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Ting Wang 
 
TRANSFER OF INTRACELLULAR HIV NEF TO ENDOTHELIUM 
CAUSES ENDOTHELIAL DYSFUNCTION 
 
          With effective antiretroviral therapy (ART), cardiovascular diseases (CVD), 
are emerging as a major cause of morbidity and death in the aging population 
with HIV infection. Although this increase in CVD could be partially explained by 
the toxic effects of combined anti-retroviral therapy (ART), more recently, HIV 
infection has emerged as an independent risk factor for CVD. However, it is 
unclear how HIV can contribute to CVD in patients on ART, when viral titers are 
low or non-detectable. Here, we provide several lines of evidence that HIV-Nef, 
produced in infected cells even when virus production is halted by ART, can lead 
to endothelial activation and dysfunction, and thus may be involved in CVD. We 
demonstrate that HIV-infected T cell-induced endothelial cell activation requires 
direct contact as well as functional HIV-Nef. Nef protein from either HIV-infected 
or Nef-transfected T cells rapidly transfers to endothelial cells while inducing 
nanotube-like conduits connecting T cells to endothelial cells. This transfer or 
transfection of endothelial cells results in endothelial apoptosis, ROS generation 
and release of monocyte attractant protein-1 (MCP-1). A Nef SH3 binding site 
mutant abolishes Nef-induced apoptosis and ROS formation and reduces MCP-1 
production in endothelial cells, suggesting that the Nef SH3 binding site is critical 
for Nef effects on endothelial cells. Nef induces apoptosis of endothelial cells 
  vi 
through both NADPH oxidase- and ROS-dependent mechanisms, while Nef-
induced MCP-1 production is NF-kB dependent. Importantly, Nef can be found in 
CD4 positive and bystander circulating blood cells in patients receiving virally 
suppressive ART, and in the endothelium of chimeric SIV-infected macaques. 
Together, these data indicate that Nef could exert pro-atherogenic effects on the 
endothelium even when HIV infection is controlled and that inhibition of Nef-
associated pathways may be promising new therapeutic targets for reducing the 
risk for cardiovascular disease in the HIV-infected population.  
 
 
  
  Louis M. Peuls Ph.D., Co-Chair 
 
 
 
  
     Matthias A. Clauss Ph.D., Co-Chair 
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INTRODUCTION 
1. HIV 
1.1 Epidemiology of HIV/AIDS 
Human immunodeficiency virus (HIV) is a single-stranded, positive-sense 
RNA lentivirus that causes acquired immunodeficiency syndrome (AIDS). HIV 
infection causes the progressive failure of the immune system, making patients 
vulnerable to life-threatening opportunistic infections and cancers (Sepkowitz 
2001). HIV/AIDS is a global pandemic, with an average of 40,000 new HIV 
infections each year (Cohen, Hellmann et al. 2008). According to the 2011 world 
AIDS report (www.unaids.org), approximately 17.2 million men, 16.8 million 
women and 3.4 million children under 15 years old were infected with HIV.  Of 
these, Sub-Saharan Africa is the region most affected: In 2010, an estimated 
68% (22.9 million) of all HIV cases and 66% of all deaths (1.2 million). In the 
United States, the CDC estimates that 1.1 million persons are living with HIV 
infection, including 18.1% who are unaware of their infection. With the 
development of antiretroviral therapies, the deaths from AIDS decreased to 1.8 
million in 2010 compared with 2.2 million in 2005. However, the deaths of 
persons with an AIDS diagnosis can be due to any cause: the death may or may 
not be related to AIDS (Cheung, Pantanowitz et al. 2005). 
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1.2 Clinical and virological aspects of HIV infection 
There are three main phases of HIV infection: acute infection, clinical 
latency and AIDS (Bartlett 1990). Within 2-4 weeks after infection with HIV, some 
individuals experience “influenza-like illness” while others do not have any 
symptoms. The duration of the symptoms varies, but usually last one or two 
weeks. This is the period when HIV virus is rapidly produced in the patient’s 
body. The initial symptoms are followed by a stage called clinical latency, 
asymptomatic HIV, or chronic HIV. This stage can last from three years to twenty 
years without any treatments. During this phase, HIV reproduces at a very low 
level, with few or no symptoms at first.  Towards the end of this phase, HIV-
patients viral load begins to rise and the CD4 cell counts decrease (Figure 1). As 
this happens, many people experience fever, weight loss, gastrointestinal 
problems and muscle pains, and some of them may also develop persistent 
generalized lymphadenopathy.  However, about 5% of HIV patients retain high 
CD4 cell counts without antiretroviral therapy (ART) for more than 5 years, and 
are considered as HIV long-term nonprogressors (LTNP) (Blankson 2010). 
Another small group of HIV-infected patients (0.03%) maintain a low or 
undetectable viral load without ART and are known as "elite controllers" or "elite 
suppressors". Once the number of CD4 cells begins to fall below 200 cells per 
µL, these patients are diagnosed as AIDS patients (Alimonti, Ball et al. 2003). At 
this stage, people with AIDS have an increased risk of developing various viral 
induced cancers including: Kaposi's sarcoma, Burkitt's lymphoma, primary 
central  
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Figure 1: Timecourse of HIV infection  
The Blue line represents CD4 cell counts while the red line represents viral load. 
Major disease progressions were labled in the figure. Adapted from Grossman, 
Meier-Schellersheim et al. 2006. 
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 nervous system lymphoma, and cervical cancer, which are less common in 
immuno-competent people. 
 
1.3 HIV genome structure 
HIV is a large virus with a diameter of about 120nm, composed of two 
copies of positive single-stranded RNA that codes for the virus's nine genes (gag, 
pol, and env, tat, rev, nef, vif, vpr, vpu). HIV is surrounded by the viral envelope 
(Lu, Heng et al. 2011). The protein, known as Env, consists of a cap made of 
three molecules called glycoprotein (gp) 120, and a stem consisting of three 
gp41 molecules that anchor the structure into the viral envelope. This protein is 
important to enable the virus to gain access into CD4+ cells to initiate the 
infectious cycle. Env together with other two genes: Gag and Pol are the 
structural genes for new virus particles. Gag encodes four structural proteins: 
matrix (MA), capsid (CA), nucleocapsid (NC), and p6 (Poon, Wu et al. 1996; 
Cimarelli, Sandin et al. 2000; Wang and Aldovini 2002). Pol encodes the viral 
enzymes: protease, reverse transcriptase (RT), and integrase (IN) (Hill, 
Tachedjian et al. 2005). These enzymes are produced as a Gag-Pol precursor 
polyprotein by the viral protease, and are important for viral development. The six 
remaining viral genes, Tat, Rev, Vpr, Vif, and Vpu (or Vpx), Nef, play regulatory 
roles in controlling the ability of HIV to infect cells, produce new copies of virus, 
or cause disease. Of these, Tat is the transcriptional transactivators for HIV’s 
landmark long terminal repeats (LTR) promoter acting by binding the trans-
activation response (TAR) RNA element (Debaisieux, Rayne et al. 2012). Rev 
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provides nuclear export of non- or incompletely-spliced HIV mRNAs (Pollard and 
Malim 1998). Vpr is required for targeting the nuclear import of preintegration 
complexes, cell growth arrest, transactivation of cellular genes, and induction of 
cellular differentiation (Bukrinsky and Adzhubei 1999). Vif prevents the activity of 
a strongly anti-HIV host factor, APOBEC3G (Zhang, Pomerantz et al. 2000). Vpu 
increases the efficiency of viral budding from the host cell by down regulate CD4 
in the endoplasmic reticulum (Bour and Strebel 1996). Nef is a multifunctional 
accessory protein (Das and Jameel 2005) (Figure 2) and will be discussed in 
subsequent sections.    
 
1.4 HIV replication cycle 
1.4.1 Entry 
HIV virus entering host cells requires HIV gp120 molecules to bind to CD4 
molecules on the host cell’s surface. In addition to the main receptor CD4 and at 
least one of two chemokine receptors: CXCR4 and CCR5, is required for viral 
entry (Chan and Kim 1998). Following binding to CD4 protein, gp120 undergoes 
a structural change exposing the chemokine binding domains allowing them to 
interact with either CXCR4 (T-tropic isolates), CCR5 (M-tropic isolates) or both 
based on their tropism. This step helps the N-terminal fusion peptide gp41 to 
penetrate the cell membrane (Wyatt and Sodroski 1998). Of note, T-tropic 
isolates refer to the virus isolated from patients later in the infection in the 
symptomatic phase that infect T cells. On the other hand, M-tropic isolates are  
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Figure 2: The structure of HIV genome.  
The HIV genome consists of 9 genes, including the structure genes Gag, Pol and 
Env; the regulatory genes Tat and Rev; and the accessory genes Nef, Vif, Vpu 
and vpr. The HIV genome also has a "Long Terminal Repeat" (LTR) at each end 
of its genome. 
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the viruses isolated from individuals early in an infection during the asymptomatic 
phase, that typically infect macrophages, but not T cells. The mutation of co-
receptors may reduce the ability of virus to infect target cells. Individuals with the 
CCR5-Δ32 mutation are resistant to infection with M-tropic isolates, as the 
mutation stops HIV from binding to the CCR5 co-receptor (Galvani and Slatkin 
2003). 
Besides the classical CD4/co-receptor mediated entry, a few non-standard 
receptors have been reported. For example, Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), a dendritic cell (DC)–
specific HIV binding protein, enhances trans-infection of T cells. DC-SIGN does 
not function as a receptor for viral entry into DC but instead promotes efficient 
trans-infection in cells that express CD4 and chemokine receptors (Pope and 
Haase 2003; Haedicke, Brown et al. 2009). Similarly, for macrophages, 
mannose-specific macrophage endocytosis receptor interacting with gp120 also 
enhances viral entry. 
 
1.4.2 Replication and transcription 
Following viral entry to the target cell, the virus's RNA and enzymes PI, 
RT, and IN enter the cytoplasm. RT allows the single-stranded RNA to be copied 
and double-stranded DNA (dsDNA) to be generated (Zheng, Lovsin et al. 2005). 
Because of the extremely error-prone process of RT, HIV is rapidly mutated and 
evades the body’s immune system. Integrase enzyme then facilitates the 
integration of this viral DNA into the cellular chromosome. Provirus (HIV DNA) is 
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replicated along with the chromosome when the cell divides. The integration of 
provirus may be dormant in the latent stage of HIV infection that enables the 
virus to evade host responses so effectively. Next, the integrated provirus is 
transcribed into mRNA including Tat, Rev, and Nef, and these are the early viral 
proteins. These mRNA are spliced into smaller pieces, and exported from the 
nucleus into the cytoplasm, where they are translated into the regulatory 
proteins. Rev binds to viral mRNAs to facilitate unspliced RNAs to leave the 
nucleus.  Meanwhile, the structural proteins Gag and Env are produced from the 
full-length mRNA (Pollard and Malim 1998).  
 
1.4.3 Assembly and release 
Assembly of new HIV virions, Env protein (gp160) is localized to lipid rafts 
in cell membrane through the Golgi complex. Gp160 is cleaved into the two HIV 
envelope glycoproteins, gp41 and gp120 (Hallenberger, Bosch et al. 1992). They 
are transported to the plasma membrane of the host cell where gp41 anchors 
gp120 to the infected cell membrane. Once the Gag and Gag-Pol polyproteins 
associate with the inner surface of the plasma membrane, HIV genomic RNA 
begins to bud from the host cell.  Gag protein is then cleaved into the actual 
matrix, capsid and nucleocapsid proteins by the packaged viral enzyme PI 
(Sundquist and Krausslich 2012). The virion now undergoes a morphological 
change and becomes mature and infectious (Figure 3). 
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Figure 3: HIV life cycle 
The important steps of HIV life cycle: 1. HIV gains the entrance to its target cell. 
2. HIV releases RNA, the genetic code of the virus, into the cell. 3. HIV RNA is 
converted to DNA by reverse transcriptase. 4. The viral DNA enters the nucleus 
of its target cell followed by integration. 5. The DNA of the infected cell now 
produces RNA and proteins that are needed to assemble a new HIV. 6. HIV viral 
assembly at the cell membrane. 7. The new mature HIV virus. 
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1.5 HIV treatment 
1.5.1 HIV vaccines 
HIV surface proteins, especially gp120, are considered as targets for 
vaccines against HIV. However, the gp120 glycosylation patterns are highly 
variable in different HIV strains, which made producing gp120 antibodies difficult.  
In this decade, several research groups brought vaccines to clinical trials, 
including the STEP study and HVTN 505 trials. The STEP study was ceased in 
2007, while HVTN 505 was stopped in 2013, both due to ineffectiveness in 
preventing HIV infections and lowering viral load among those participants who 
had become infected with HIV. In a recent report, a new vaccine has just finished 
FDA Phase I Clinical Trials and has shown promising results. This vaccine uses 
HIV that has been genetically engineered to make it non-infectious, which 
reduces the risk of causing HIV in the recipient compared to making a vaccine 
from whole, killed virus. HIV patients with vaccine intake had as much as 64 
times more antibody against the p24 capsid antigen and up to eight times higher 
antibody against gp120 surface antigen than initial titers. And there were no 
major side effects or reactions to the vaccine reported.  However, the Phase II 
and Phase III trials still have to be run, where most other vaccines had been 
deemed failures. 
 
1.5.2 ART 
Antiretroviral therapy dramatically improves the health and prolongs the 
lives of persons with HIV (Cooper, Nugent et al. 1996). ART efficiently decreases 
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patient’s viral loads, maintains function of their immune system, and prevents 
opportunistic infections. Studies also showed that using ART can reduce the risk 
of sexually transmitting HIV by 90%. ART normally combines at least three 
antiretroviral drugs from at least two different categories. There are five 
categories of drugs which attack HIV in different ways, including nucleoside 
reverse transcriptase inhibitors (NRTI)/nucleotide reverse transcriptase inhibitors 
(NtRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease 
inhibitors (PIs), viral entry inhibitors and integrase inhibitors (Table 1). 
The first approved antiretroviral drugs (1987) NRTI and NtRTI are 
nucleoside and nucleotide analogues, lacking a 3'-hydroxyl group on the 
deoxyribose moiety, which inhibit reverse transcription. NRTIs need to be 
activated for viral DNA incorporation by addition of three phosphate groups to 
their deoxyribose moiety, to form NRTI triphosphates. In contrast, non-nucleoside 
analogs block reverse transcriptase by binding to RT. PIs block the viral protease 
enzyme, preventing cleavage of gag and gag/pol precursor proteins. Thus, the 
newly made virus particles in this case are defective and mostly non-infectious. 
The side effects of first generation PIs that have been reported include causing a 
syndrome of lipodystrophy, hyperlipidaemia, diabetes mellitus type 2 and kidney 
stones. New generation drugs have been developed that are less toxic and are 
effective against some HIV variants that are resistant to first generation PIs. 
Integrase inhibitors inhibit the enzyme integrase, which is responsible for 
integration of DNA from virus into the target cell. Currently, there are only two 
FDA approved integrase inhibitors: raltegravir (2007) and the latest one 
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Elvitegravir (2013), but several others are currently in clinical trials. Entry 
inhibitors interfere with virus binding, fusion and entry to the host cell by blocking 
its receptors. There are two FDA approved entry inhibitors: Maraviroc (targeting 
CCR5) and enfuvirtide (targeting CXCR4).  However, using this class of drugs 
has a risk of tropism shift, which allows HIV to target an alternative co-receptor. 
Fuzeon (enfuvirtide), a peptide drug can act by interacting with the N-terminal 
heptad repeat of gp41 of HIV to form an inactive hetero six-helix bundle, 
therefore preventing infection of host cells. 
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Catogory Brand Name Generic Names 
 Epivir Lamivudine 
 Emtriva Emtricitabine 
NRTIs Retrovir Zidovudine, 
azidotymidine  Trizivir Abacavir, 
zidovudine, 
lamivudine 
 Zerit Sta i  
 Ziagen Ab ca ir sulfate 
NNRTIs 
Edurant Rilpivirine 
Intelence Etravirine 
Rescriptor Delavirdine 
Sustive Efavirenz 
Viramune Nevirapine 
PIs 
Agenerase Amprenavir 
Crixivan Indinavir 
Norvir Ritonavir 
Prezista 
Reyataz 
Fuzeon 
Isentress 
EVG 
 
Darunavir 
Reyataz Atazanavir sulfate 
Entry  
Inhibitors 
Fuzeon Enfuvirtide (T-20) 
Selzentry Maraviroc 
Intergrase 
inbitorrs 
Isentress Raltegravir 
EVG Elvitegravir 
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Table 1: FDA-approved antiretroviral drugs 
Data collected from FDA website www.fda.gov/oashi/aids/virals. 
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2. HIV negative factor (Nef) 
2.1 Nef expression and structure 
Nef is a ~27 kDa accessory protein that is devoid of enzyme activity. It is 
found at the 3’ end of the HIV genome, overlapping the 3’LTR (See Figure 2). 
Nef is N-terminal myristoylated, which is crucial for its membrane targeting. The 
Nef core domain structure resembles that of the helix-turn-helix (HTH) family of 
proteins involved in binding DNA. One of the most important motifs for Nef 
function is the proline-rich Src homology-3 (SH3) domain-binding sequence 
(PxxP), allowing Nef to bind to SH3 domain-containing proteins, such as Src, 
Lck, and Hck. This binding site is required for Nef to associate with a P21 
activated kinase (PAK)-Related Kinase, and Nef-induced alterations of signal 
transduction in T cells. In addition, The Nef N-terminal stretch of basic residues 
can contribute to Nef membrane localization: an acidic region (62EEEE65) is 
responsible for Nef perinuclear localization, while three pairs of amino acid 
residues (W57/L58, L164/L165, and D174/D175) act to alter the surface 
expression of many cellular proteins, such as down regulating CD28 expression 
(Figure 4). 
 
2.2 Nef protein function in HIV 
2.2.1 Nef as a positive viral factor 
Nef is an important HIV pathogenic factor, as demonstrated by in vivo 
studies. Studies in Rhesus monkeys have demonstrated that Nef is critical for 
attaining high virus loads and development of AIDS-like disease in SIV-infected 
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macaques. In parallel, studies on SCID-hu mice also demonstrated that nef-
deleted HIV strains showed significantly lower levels of infectivity and 
pathogenicity. A recent study also demonstrated that transgenic mice expressing 
CD4-promoter driven Nef develop a spectrum of pathologies including AIDS-like 
disease. More importantly, in clinical studies, patients infected with a HIV Nef-
deletion or Nef allele mutant strains showed lack of disease progression. 
However, Nef either has no effect or a positive effect on viral replication in vitro 
depending on cell types. Nef generally has no effect on viral replication in 
activated peripheral blood mononuclear cells (PBMCs) and activated CD4+ T 
cells, but plays a significant role in post infection-stimulated PBMCs or lymphoid 
cultures, immature dendritic cell-T cell co-cultures and in the ex vivo tonsil culture 
system. 
Productive HIV infection is regulated by Nef-induced lymphocyte-
stimulating factor release from macrophages. This provides an environment 
where Nef itself can stimulate viral replication by increasing the pool of 
lymphocytes. In addition, HIV Nef also facilitates the incorporation of Nef-
associated cellular kinases that phosphorylate various substrates, including viral 
matrix protein necessary for generating fully infectious viral particles.  
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Figure 4: Residues of HIV Nef protein 
 Important Nef residues are labeled above the figure:  The Nef N-terminal stretch 
of basic residues can contribute to Nef membrane localization; an acidic region 
(62EEEE65) is responsible for Nef perinuclear localization; the proline-rich Src 
homology-3 (SH3) domain-binding sequence (PxxP); the and three pairs of 
amino acid residues (W57/L58, L164/L165, and D174/D175) act to alter the 
surface expression of many cellular proteins. 
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2.2.2 Nef alleles show major differences in pathogenicity  
Nef is a major determinant of panthogenicity in persons. Various Nef 
alleles were reported to show differences in pathogenicity, including SF2, JR-
CSF, YU10x, and NL4-3 [T71R] Nef alleles, as well as some from long-term 
nonprogressors (AD-93, 032an, and 039nm alleles). Except YU10x, all these Nef 
alleles down regulated cell surface CD4 in human cells in vitro, and depleted of 
double-positive and single-positive thymocytes. A loss of peripheral CD4 T cells 
was observed with all alleles but was minimal in Nef YU10x Tg mice. Of these 
alleles, Nef032an and Nef SF2 are highly virulent; associated with severe T-cell 
loss. Moreover, all Nef alleles except the Nef YU10x and Nef NL4-3(T71R) 
alleles induced an enhanced activated memory (CD25(+) CD69(+) CD44(high) 
CD45RB(low) CD62L(low)) and apoptotic phenotype. Also, all could interact with 
and/or activate PAK2 except the Nef JR-CSF allele. Nef NL4-3(T71R), Nef 
032an, Nef 039nm, and Nef SF2 Tg mice, but not Nef YU10x Tg and NefAD-93 
mice, developed organ (lung and kidney) diseases (Priceputu, Hanna et al. 
2007).  
 
2.2.3 Nef alters cell surface expression of critical proteins 
Nef protein was reported to down regulate several important proteins 
involved in the immune synapse, including CD4, MHC I, MHCII, CD28, NKG2D, 
CXCR4, and CD80(Le Gall, Erdtmann et al. 1998; Swigut, Shohdy et al. 2001; 
Blagoveshchenskaya, Thomas et al. 2002; Chaudhry, Das et al. 2005; Cerboni, 
Neri et al. 2007; Chaudhuri, Lindwasser et al. 2007). It is not fully understood 
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how Nef affects these proteins, but in most case, Nef down regulates these 
proteins by interacting with adaptor protein complexes AP-1, AP-2, AP-3, 
Clathrin, and PACS-1 (Foti, Mangasarian et al. 1997; Le Gall, Erdtmann et al. 
1998; Lock, Greenberg et al. 1999). 
 
2.2.4 Nef alters T cell receptors and cellular signaling pathways 
Nef targets various signaling pathways, including the T cell receptor (TcR) 
signalling pathway (Luo and Peterlin 1997; Djordjevic, Schibeci et al. 2004), IL-2 
receptor pathway (Greenway, Azad et al. 1995; Schrager and Marsh 1999), 
pathways in macrophages leading to chemokine production as well as the anti-
apoptotic cascade. Nef binding to SH3 domains of the Src family of kinases p21 
activated protein kinase (PAK2) is important for signal transduction alteration in T 
cells, such as inducing rapid and transient phosphorylation of the α and ß 
subunits of the IκB kinase complex and of JNK, ERK1/2 as well as p38 mitogen-
activated protein kinase family members (Rudel, Zenke et al. 1998). In addition to 
the effects in infected cells, Nef has been shown to induce the formation of 
exosomes (Lenassi, Cagney et al. 2010) to cause cell death in bystander T cells 
and formation of nanotubes, which physically connect to bystander cells 
(Sowinski, Jolly et al. 2008). In infected monocytes, Nef induces nanotube-like 
conduits that can connect to B cells and mediate its own transfer to B cells where 
it inhibits Ig class switching (Qiao, He et al. 2006; Xu, Santini et al. 2009). 
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3. Cardiovascular diseases 
3.1 Coronary artery disease (Atherosclerosis) 
3.1.1 Cholesterol-dependent 
Atherosclerosis refers to hardening of arteries that results from a chronic 
inflammatory response in the walls of arteries. It is caused by the accumulation of 
macrophages and white blood cells and promoted by low-density lipoproteins 
(LDL) (Ross 1999). Endothelial dysfunction is an early precursor to 
atherosclerosis and has been shown to predict future cardiovascular events in 
most population studies, which is defined as an imbalance between vasodilating 
and vasoconstricting substances produced by the endothelium (Deanfield, 
Donald et al. 2005). The normal arterial endothelium resists prolonged contact 
with leukocytes including the blood monocyte. Once endothelial cells undergo 
inflammatory activation, they attract monocytes by increasing adhesion molecule 
expression, such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) (Cybulsky, Iiyama et al. 2001). The activated 
endothelial cells secrete various chemokines, including monocyte 
chemoattractant protein-1 (MCP-1), which allow monocytes to penetrate into the 
intima, the innermost layer of the arterial wall (Aiello, Bourassa et al. 1999). After 
the monocyte acquires characteristics of the tissue macrophage, in the atheroma 
in particular, scavenger receptors on these macrophages bind to modified LDL 
by oxidation or glycation. These processes give rise to the arterial foam cell, a 
hallmark of the arterial lesion. The foam cell then secretes pro-inflammatory 
cytokines that amplify the local inflammatory response and reactive oxygen 
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species (ROS) production in the lesion (Mugge 1998). Matrix metalloproteinases 
(MMPs) production can degrade extracellular matrix, followed by the plaque 
ruptures, and eventually induce thrombus formation in the lumen (Figure 5).  
 
3.1.2 Other risk factors: Cholesterol-independent 
Smoking 
Cigarette smoking (CS) is known to increase the incidence of myocardial 
infarction (MI) and fatal coronary artery disease (CAD), even for light smokers. 
Passive CS is associated with a 30% increased risk of CAD, compared with an 
80% increase in active smokers (Jeremy, Mikhailidis et al. 1995; Ambrose and 
Barua 2004). Cigarette smoking impairs endothelium-dependent vasodilation 
through decreasing nitric oxide (NO) availability. NO is not only a vasoregulatory 
molecule, but it also helps regulate inflammation, leukocyte adhesion, platelet 
activation, and thrombosis (Napoli and Ignarro 2001). Thus, an alteration in NO 
biosynthesis could have both primary and secondary effects on the initiation and 
progression of atherosclerosis. Cigarette smoking also increases levels of 
inflammatory markers including C-reactive protein (Tracy, Psaty et al. 1997), 
interleukin-6 (IL6), and tumor necrosis factor alpha (TNFα) (Mendall, Patel et al. 
1997). Furthermore, CS could promote atherosclerosis by its effects on lipid 
profile (Craig, Palomaki et al. 1989). Though the mechanism behind this was not 
fully understood, triglyceride/LDL abnormalities have been suggested to be 
related to insulin resistance. More importantly, CS increases oxidative 
modification of LDL that exposure to CS extract caused a modification of LDL 
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that promoted the formation of foam-cells, and it may also decrease the plasma 
activity of paraoxonase, an enzyme that protects against LDL oxidation (Yokode, 
Kita et al. 1988; Pech-Amsellem, Myara et al. 1996). 
Diabetes 
It is known that coronary heart disease is correlated with both type 1 and 
type 2 diabetes mellitus (Nathan, Lachin et al. 2003). These diabetic patients fail 
to achieve significant reduction in macrovascular events, which may be explained 
by diabetes-related metabolic abnormalities accelerating macrovascular 
complications. In some animal models, diabetes-induced hyperlipidemia occurs 
and may mask toxic effects of hyperglycemia that confer diabetes-specific risk. 
These effects may be caused by the development of increasing advanced 
glycation end products (AGEs) level, toxic intracellular reactions to glucose 
secondary to the production of increasing ROS level, and multiple effects on the 
production of matrix proteins and the biology of cells within the vessel wall 
(Brownlee 2001). 
 
3.2 HIV-related cardiovascular diseases 
3.2.1 ART in coronary artery disease 
Acute coronary syndromes are observed with increasing frequency among 
HIV patients receiving therapy with protease inhibitors as part of ART regimens. 
Several studies reported that currently available HIV PIs are associated with 
increased levels of total cholesterol (36 [75%] of 48 studies), triglycerides (35 
[73%] of 48 studies), and low-density lipoprotein (12 [100%] of 12 studies).  
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Protease inhibitor was also found to increase carotid intima thickness or 
atherosclerotic lesions (7 [88%] of 8 studies) (Rhew, Bernal et al. 2003). In 
particular, HIV PIs (ritonavir, indinavir, and atazanavir), caused the accumulation 
of free cholesterol in intracellular membranes, depleted endoplasmic reticulum 
calcium stores, activated caspase-12, increased apoptosis in macrophages and 
promoted atherosclerosis and cardiovascular disease in HIV-infected patients. 
The most substantial database has recently been provided by the D:A:D study 
group who demonstrated an increased incidence of myocardial infarction in HIV-
infected persons on PIs or NtRTIs-containing therapy in a prospective 
observational cohort study. In a contrast, SMART (Strategies for Management of 
Anti-Retroviral Therapy) analysis revealed slightly elevated risk of cardiovascular 
disease in people who interrupt therapy, which implied that there are other 
factors may potentially increase HIV-cardiovascular diseases (McClay, David 
Fourteenth Conference on Retroviruses and Opportunistic Infections).  
 
3.2.2 HIV viron-related cardiovascular disease 
Controversy currently exists on whether people living with HIV and taking 
ART have greater cardiovascular risks than treatment-naive HIV-infected 
individuals. Untreated HIV infection has been found to associate with increased 
levels of IL6. Higher levels of IL-6 strongly predict cardiovascular events and 
overall mortality in antiretroviral-untreated and treated HIV infection (Kuller, Tracy 
et al. 2008).  
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Figure 5: The process of atherosclerosis. 
The schematic is the representation of atherosclerotic process. Monocytes recruit 
when adhesion molecules (e.g VCAM I and ICAM) express on endothelium. 
Once resident in the arterial intima, activated macrophages become 
phagocytically active.  Followed by the macrophages take up enough cholesterol 
and become foam cells. Foam cells release growth factors that stimulate the 
growth of nearby smooth muscle cells and fibroblasts. Smooth muscle cells 
migrate from the tunica media into the intima. Once they deposit additional 
connective tissue, the abnormal region becomes a fibrous plaque. Ruptures of 
the fibrous cap expose thrombogenic material to the circulation and eventually 
induce thrombus formation. 
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HIV infection is reported to be associated with premature atherosclerosis. 
This occurs even in the absence of detectable viremia, overt immunodefiency 
and exposure to ART and appears to be independent of traditional CD4+ T cell 
count. C-reactive protein was higher in HIV cardiac risk factors. They measured 
401 HIV-seropositive participants by assessing carotid artery intima-media 
thickness (IMT) and found that IMT was strongly associated with the presence of 
HIV disease rather than viral load or controllers than HIV-seronegative persons. 
However, ART was also associated with higher IMT (Hsue, Hunt et al. 2009). 
Recent studies have shown that acute myocardial infarction (AMI) rates and 
cardiovascular risk factors were increased in HIV compared with non-HIV 
patients [11.13 (95% confidence interval [CI] 9.58-12.68) vs. 6.98 (95% CI 6.89-
7.06)], particularly among women (Triant, Lee et al. 2007). Even though there 
were no reports showing that HIV-infected patients with the metabolic syndrome 
(MS) have a faster rate of progression of coronary atherosclerosis, Fitch et al 
reported that HIV-infected men with MS have higher cardiac risk factor - coronary 
artery calcium (CAC) score when compared to HIV-infected and non HIV-infected 
control groups with similar demographic parameters, age and smoking rates 
(Ullrich, Groopman et al. 2000). They also found that presence of plaque and 
numbers of noncalcified plaque segments were increased among both HIV-
infected groups compared with HIV negative controls. Both of the evidence 
suggested that HIV patients without significant metabolic abnormalities may still 
develop noncalcified plaque and be at increased risk for coronary artery 
diseases. 
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3.2.3 HIV proteins in cardiovascular disease 
Endothelial dysfunction injury is pivotal to the development of 
cardiovascular disease in HIV-infected patients (Chi, Henry et al. 2000). 
Endothelial dysfunction is defined as an imbalance between vasodilating and 
vasoconstricting substances produced by the endothelium (Deanfield, Donald et 
al. 2005). Endothelial dysfunction can result from or contribute to coronary artery 
disease, and other atherosclerotic diseases (Flammer, Anderson et al. 2012). 
The previous studies showed that endothelial “activation”, in the form of soluble 
adhesion molecules and procoagulant proteins, led to a pro-inflammatory, 
proliferative and prothrombotic state of the endothelium occurs. Proinflammatory 
cytokines (e.g IL-6, TNF alpha) and HIV proteins are contributory to endothelial 
dysfunction.  
HIV envelope glycoprotein (HIV gp120) 
HIV DNA or RNA was only found in inflammatory cells of heart tissues 
from HIV patients with or without HIV cardiomyopathy (HIVCM) but not 
endothelial cells or cardiomyocytes. Interestingly, HIV gp120 was exhibited in 
both of these cells (Fiala, Popik et al. 2004). Recombinant HIV gp120 protein has 
been shown to damage the endothelium by interaction with CXCR4 (Fiala, 
Murphy et al. 2004), and this induced endothelial apoptosis mediated by 
activating caspase 3,9 and by slightly enhancing expression of the pro-apoptotic 
molecule, Bax (Kanmogne, Primeaux et al. 2005). HIV gp120 was also reported 
to be able to reduce endothelial nitric oxide synthase (eNOS) expression in TNF-
α-activated endothelial cells; HIV gp120 and TNF-α have synergistic effects on 
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inhibition of eNOS expression in endothelial cells (Jiang, Fu et al. 2010). Use of a 
primary human lymphatic endothelial cell model, HIV gp120 induced lymphatic 
hyperpermeability by disturbing the normal function of Robo4, a novel regulator 
of endothelial permeability. Moreover, pretreatment with an active N-terminus 
fragment of Slit2, a Robo4 agonist, protected lymphatic endothelial cells from HIV 
gp120-induced hyperpermeability by inhibiting c-Src kinase activation (Zhang, Yu 
et al. 2012).  
HIV secreted protein: Tat protein 
HIV Tat protein has been found to significantly decrease endothelium-
dependent vasorelaxation and eNOS mRNA and protein expression in 
endothelial cells of porcine coronary arteries (Diaz, King et al. 2000). Tat is also 
known to cause apoptosis of primary microvascular endothelial cells of lung 
origin via a mechanism distinct from tumor necrosis factor secretion or the Fas 
pathway. On the other hand, Tat protein dissemination to extravascular tissue 
can activate human endothelial cells by expressing the endothelial-leukocyte 
adhesion molecules, E-selectin, critical for the initial binding of leukocytes to the 
blood vessel wall, and their increased synthesis of IL-6, a cytokine known to 
enhance endothelial cell permeability (Hofman, Wright et al. 1993).  Tat protein is 
also found to play a role in HIV-related pulmonary hypertension through several 
different mechanisms: In the most recent study, the exposure of HUVECs to HIV 
Tat protein resulted in induced expression of cell adhesion molecule ICAM-1 
through activation of mitogen-activated protein kinases and downstream 
transcription factor NF-κB., leading to increased adhesion of monocytes to the 
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endothelium (Magalhaes, Greenberg et al. 2007); Three receptors: the integrins 
αvβ3, α5β1 and the vascular endothelial growth factor receptor-2 (VEGFR-
2/KDR) were reported to interact with Tat protein, and help Tat protein gain 
access to endothelium (Albini, Soldi et al. 1996; Barillari, Sgadari et al. 1999; 
Mitola, Soldi et al. 2000; Kline and Sutliff 2008). These findings further support 
the concept of how Tat protein causes aberrant cell signaling and leads to altered 
endothelial cell morphology, gene expression, and survival.  
HIV Nef protein 
There have been many reports of low-level transcription of HIV genes 
even after years of ART (Furtado, Callaway et al. 1999; Fischer, Gunthard et al. 
2000; Gunthard, Havlir et al. 2001). Further analysis has shown that the multiply-
spliced mRNAs, the “early” HIV genes Tat, Rev, and Nef, decrease to a lesser 
extent than other HIV gene products after initiation of treatment (Fischer, Joos et 
al. 2008) suggesting that these may play a role in mechanisms of cardiovascular 
damage even in patients on ART. In fact, intracellular mRNA encoding Nef 
showed the cellular viral rebound in PBMCs during therapy and was 
subsequently triggered by the plasma viremia that preceded the recurrence 
(Fischer, Joos et al. 2004). When Nef is expressed specifically in CD4+ cells in 
CD4.Nef Tg mice, Nef can cause development of AIDS-like phenotypes, 
cardiovascular disease and coronary vascular dysfunction (Fischer, Joos et al. 
2004; Hanna, Priceputu et al. 2009; Jolicoeur 2011). Although no reported 
studies have directly assayed the effect of Nef on coronary arteries, Nef has 
been shown to be involved in pulmonary arterial dysfunction. Macaques infected 
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with a chimeric simian immunodeficiency virus (SIV) containing the HIV-nef gene 
(SHIV-Nef) exhibited vasculopathies similar to those in human pulmonary 
hypertension (PH) (Sehgal, Mukhopadhyay et al. 2009). Importantly, 10 
polymorphisms in Nef were significantly more frequent in blood cells or lung 
tissue specimens from individuals with HIV and pulmonary hypertension 
compared to HIV-infected individuals without PH, suggesting the possibility of 
linking particular Nef sequences with specific pathogenic functions of Nef, i.e. 
ability to transfer to bystander cells. 
HIV Nef protein has also been shown to block ATP-binding cassette 
transporter A1-dependent cholesterol efflux, resulting in the accumulation of 
lipids in macrophages, a condition previously shown to be highly atherogenic 
(Mujawar, Rose et al. 2006). There are at least two mechanisms involved for this: 
HIV infection and transfection with Nef induced post-transcriptional down 
regulation of ABCA1; and Nef mediated redistribution of ABCA1 to the plasma 
membrane and inhibited internalization of apolipoprotein A-I. Mutations in ABCA1 
cause Tangier disease, which is associated with low HDL cholesterol and 
accelerated atherosclerosis (Oram and Lawn 2001). Importantly, HDL cholesterol 
levels are reduced in untreated HIV infection, which is greater than the ART 
effect (Grunfeld, Pang et al. 1992; Shafran, Mashinter et al. 2005; Carr and Ory 
2006; Johnson, Gathe et al. 2006).   
Other HIV proteins 
One group quantified the role of expression of HIV-1 proteins on the 
vascular function, biomechanics, and geometry of common carotid arteries and 
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aortas by accessing NL4-3Δ gag/pol transgenic mice (HIV-Tg). These HIV-Tg 
mice have been found to have impaired aortic endothelial function, increased c-
IMT, and increased arterial stiffness; and decreased elastin content, increased 
cathepsin K and cathepsin S activity, and increased mechanical residual stress 
(Hansen, Parker et al. 2013).  
  
  36 
4. Summary of background and the hypothesis of this study 
Cardiovascular disease is emerging as a major cause of morbidity and 
mortality in the increasingly aging HIV-infected population. A hallmark of many of 
these diseases is evidence of chronic vascular inflammation. Although side 
effects of combined anti-retroviral therapy (ART) could be blamed for some 
increases in CVD, it is becoming evident that HIV infection is an independent risk 
factor for CVD. However, it remains a mystery how HIV can contribute to CVD in 
patients on ART, when viral titers are low or non-detectable. One possible 
explanation could be persistence of toxic viral products despite control of viral 
replication and viremia. In this regard, a myristoylated intracellular protein, Nef, 
has been shown to be produced in infected cells even after virus production is 
halted by ART. Endothelial cells, especially in developing atherosclerotic 
plaques, are in direct contact with circulating HIV-infected cells and in a prime 
position for Nef transfer. Therefore, my primary hypothesis is that Nef may also 
transfer to vascular endothelial cells and thus lead to endothelial activation, 
dysfunction and potentially progression to atherosclerosis. In this study, we 
propose a model in which Nef can mediate its transfer from Jurkat T cells to 
endothelial cells to trigger endothelial dysfunction. We further demonstrate that 
Nef contributes to endothelial dysfunction via two independent mechanisms, (1) 
apoptosis of endothelial cells through an NADPH oxidase-dependent mechanism 
and (2) MCP-1 production through the NF-κB signaling pathway.  
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MATERIALS AND METHODS 
Materials  
Mediums and supplements 
Roswell Park Memorial Institute 1640(RPMI-1640) medium, Eagle Basal 
medium-2 (EMB-2), penicillin, and endothelial cell growth bullet kit-2 (EGM-2MV) 
were purchased from Lonza (Walkersville, MD). EGM-2MV contains 5% FBS, 
0.4% hydrocortisone, 0.4% hFGF, 0.1% VEGF, 0.1% IGF-1, 0.1% ascorbic acid, 
0.1% hEGF, 0.1% GA-100 (Gentamicin, Amphotecerin B), and 0.1% heparin. 
Fetal bovine serum (FBS) was purchased from Hyclone sterile systems (Logan, 
UT). All bacterial culture materials were purchased from Becton Dickenson 
(Sparks, MA). The bacterial culture media were prepared in house, including 
Luria broth (LB) media containing 0.01 g/ml Bacto tryptone, 0.005 g/ml Bacto 
yeast extract, 0.005 g/ml NaCl, and 1 mM NaOH, with the addition of 15 g/L 
Bacto agar to make solid LB culture plates. Super optimal broth with catabolite 
repression (SOC) contained 0.02 g/ml Bacto tryptone, 0.005 g/ml Bacto yeast 
extract, 0.5 g/ml NaCl, 10mM MgCl2, 10 mM MgSO4, and 20 mM glucose. 
Working concentrations of antibiotics were 100 µg/ml ampicillin and 50 µg/ml 
kanamycin, and they were purchased from Sigma-Aldrich (St Louis, MO). 
 
Antibodies 
Mouse anti-Nef EH1 antibody (IF 1:100; Flow 1:25) was obtained from the 
NIH AIDS Reagent Repository, Mouse anti-Nef 3D12 antibody (Flow 1:25), 
mouse anti-CD4 marker (Flow 1:50), phycoerythrin (PE)-conjugated anti-CD19 
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antibody and PE 650 donkey anti-sheep (IF 1:200) were purchased from Abcam 
(Cambridge, MA), Rabbit anti-p65 antibody (WB 1:1000) was purchased from 
Cell Signal Technologies (Danvers, MA). PE-conjugated phalloidin (IF 1:100), 
and AlexaFluor 488 goat anti-mouse (IF 1:200) were from Invitrogen (Carlsbad, 
CA). Normal mouse IgG, mouse anti-GAPDH (WB 1:5000), and anti-mouse HRP 
(WB 1:3000) were from Sigma-Aldrich. 
 
Reagents 
Live dye Vybrant DIO and JC-1 dye were obtained from Life Technologies 
(Grand Island, NY). The Lipofectamine LTX system was purchased from 
Invitrogen. Trolox, Apocynin, and IκB kinase inhibitor (IKKi), were purchased from 
Abcam. P65 siRNA was purchased from Cell Signal Technologies. Western 
Blotting 4–20% bis-Tris polyacrylamide gels and ECL chemiluminesence 
reagents were purchased from Thermoscientific (Walthem, MA). Protease 
inhibitor cocktail set, immunoflourescent mounting buffer, and collagen were 
purchased from Sigma-Alrich. Anti-PE microbeads were purchased from Miltenyi 
Biotec (Auburn, CA). All other chemicals were purchased from Fisher scientific 
(Hampton, New Hampshire). 
 
Biotechnological systems 
Wizard® Plus Maxipreps DNA Purification System was purchased from 
Promega (Madison, WI). RT assay kit was purchased from Roche diagnostics 
(Indianapolis, IN). Nef enzyme-linked immunosorbent assay (ELISA) Kit was 
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purchased from ImmunoDX (Woburn, MA). MCP-1 Elisa kit was purchased from 
R&D Systems (Minneapolis, MN). In Vitro Vascular Permeability Assay kit was 
purchased from Fisher. Caspase 3 detection kit was purchased from Sigma-
Aldrich. Apo-Brdu apoptosis detection kit and CPT™ Cell Preparation Tube with 
Sodium Citrate was purchased from BD biosciences (Franklin Lakes, NJ). 
 
Animals 
Macaque heart tissues were obtained from a cohort of male Indian rhesus 
macaques (Macaca mulatta) infected with SHIVnefSF33, at 1000 TCID50 per 
animal [21]. The animals were housed at the California National Primate 
Research Center in accordance with the standards of the “Guide for the Care 
and Use of Laboratory Animals” and the American Association for Assessment 
and Accreditation of Laboratory Animal Care. Necropsies were performed 
between 37-62 weeks post-infection, when the animals showed signs of 
immunodeficiency. Mouse heart tissues were obtained from University of 
Montreal from mice age 3 to 6 month housed according to institutional 
biosafety/AWA regulations and protocols. These transgenic mice have Nef and 
GFP or GFP itself expressed under the regulatory sequences of the human CD4 
gene promoter. The experiments described in this study used formalin-fixed, 
paraffin-embedded heart tissues from these animals. 
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Cells 
Cell lines 
Human coronary artery endothelial cells (HCAEC) and Human umbilical 
vein endothelial cells (HUVEC) were obtained from Lonza. Jurkat cells and THP1 
cells were purchased from American Tissue Culture Collection (ATCC, 
Manassas, VA). 
 
Cell culture 
HCAEC and HUVEC were maintained in culture medium consisting of 
Eagle’s basal medium-2 (EMB-2), 5% FBS, 0.4% hydrocortisone, 0.4% hFGF, 
0.1% VEGF, 0.1% IGF-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-100 
(Gentamicin, Amphotecerin B), and 0.1% heparin. Jurkat cells, THP1 cells and 
PBMCs were cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum and 100 U/ml penicillin. All cell cultures were maintained at 37 oC 
in 5% CO2 and 95% air. Culture medium was changed every two days. 
 
Isolation of PBMCs from HIV patients blood 
Peripheral blood from HIV patients was obtained from Indiana University 
hospital (Indianapolis, IN). Immediately after blood draw, CPT tubes with 
patients’ blood were centrifuged for a minimum of 20 minutes at 1500-1800 with 
the brake on. The white layer of PBMCs was extracted, and then washed in 40 
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ml PBS three times by centrifugation at 440 x g for 5 min.  This study was done 
under IRB approval. 
 
Plasmids and viruses 
Viruses 
pNL4-3 and pNL4-3∆Nef were obtained from the NIH AIDS Reagent 
Repository.  
 
Nef and Nef mutants 
Nef.SF2 and Nef∆SH3 mutant were obtained from the NIH AIDS Reagent 
Respository.  Nef∆SH3 mutant has a point mutation from Proline (PXXP) to 
Alanine (AXXA) in a conserved motif (aa72-75). 
 
Methods 
Bacterial transformation 
GC5™ cells were mixed with 0.5µl DNA ligation reaction, and incubated 
on ice for 20 min. The cells were heat-shocked at 42 °C for 45 sec, followed by 
incubation on ice another 2 min with 1ml RT SOC medium. The cells were then 
incubated at 37 ºC, for 1 h with shaking at 250 RPM. The cells were plated on LB 
plates with either ampicillin or kanamycin. 
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Cell transfections 
HCAEC or Jurkat cells were transfected using the Lipofectamine LTX 
system (Invitrogen) according to the manufacturer’s directions. pcDNA3 was 
used in the studies for normalization.  
 
HIV replication assay 
HIV NL4.3 or HIV NL4.3-Nef deficient virus was produced by transfection 
of 293T cells. Transfection was performed with Lipofectamine LTX reagent 
(Invitrogen), according to manufacturer’s instructions. Viral supernatant was 
harvested at 48 h and centrifugated at 900 g for 10 min, to clarify the supernatant 
from remaining cells. Viral supernatant was used to infect Jurkat cells 
corresponding to a 10,000 cpm RT activity (equivalent to 1 ng/ml RT according to 
assay protocol (Roche). Virions in the supernatant were pelleted by 
centrifugation at 12,000 g for 1 hr and the RT activity was determined every other 
day for 9 days using the RT assay kit according to the manufacturer's instruction. 
Infected cells were cocultured with HCAEC when virus titers were the same in 
both infected cells. 
 
Tissue culture based assays 
For analysis using different pharmaceutical inhibitors, HCAEC were 
seeded in 6-well plates. Nef plasmid was transfected into HCAEC by 
Lipofectamine LTX reagent (Invitrogen). The transfection efficiency was ~70% as 
determined by FACS. After 6 h post transfection, culture medium was changed, 
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and inhibitors were added at optimized concentrations (200 nM Apocynin 
(Abcam), 200 nM Trolox (Abcam), and 100 nM Ikki (R&D Systems)). After a 
further 24 h, the supernatant was collected and analyzed for MCP-1 production 
assessed by sandwich ELISA (Quantikine, R&D Systems) and the cells were 
harvested for apoptosis analysis. For coculture working models, pcDNA only 
(mock control) or Nef-containing pcDNA plasmid was transfected into Jurkat cells 
by Lipofectamine LTX reagent. At 48 h post transfection, these Jurkat cells were 
cocultured with HCAEC in a 2:1 ratio (in some cases, inhibitors were added at 
optimized concentrations as described). After 24 h co-culture, the medium was 
centrifuged to remove Jurkat cells and the supernatant collected for analysis of 
MCP-1 production. Any remaining Jurkat cells were washed off with PBS and 
further gated from endothelial cells by FACS, based on forward scatter and side 
scatter profiles. HCAEC were harvested for apoptosis analysis. 
 
Detection of apoptosis by assessing DNA fragmentation (TUNEL) 
Apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick 
end labeling in endothelial cells was performed as previously described (Green, 
Petrusca et al. 2012). Detection of apoptosis by FACS via a modified TUNEL 
approach was carried out using a fluorescence labeling system to detect dUTP 
end nicks according to the manufacturer's instructions (APOBRDU kit, Becton 
Dickinson). 
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Confocal immunofluorescence microscopy 
 
For in vitro studies, Nef and cDNA transfected Jurkat cells were stained 
with cytoplasm live dye Dyvant DIO (Life Technologies) (5ul live dye/1 million 
cells at 37ºC for 1 h), and cocultured with HCAEC for 24 h. Cells were fixed in 
4% paraformaldehyde, permeabilized with 0.01% Triton X-100 in PBS (20 min at 
4°C) and stained with 10 uM phalloidin and in some cases, anti-Nef EH1 
antibody. Visualization was achieved by confocal microscopy (Olympus FV1000-
MPE) with the same fluorescence intensities during image acquisition. The 
derived images were analyzed using MetaMorph software.  
 
In Vitro Vascular Permeability Assay 
HCAEC were plated on transwell insert of 24 well Corning® Costar® cell 
culture plate with 0.5 ml EGM-2MV growth media. Nef was transfected to 80% 
confluent HCAEC for 24 h. One hundred fifty milliliters of FITC-Dextran working 
solution was added to each insert for 20 min at room temperature in the dark. 
One hundred milliliters of media was removed from each well for fluorescence 
measurement at 485 nm and 535 nm excitation and emission, respectively. 
  
Ex vivo tissue sections staining 
For staining mice and macaque heart sections, slides were de-paraffinized 
and processed as recently described (Marecki, Cool et al. 2006). Briefly, sections 
were stained with anti-GFP (for macaque), or anti-Nef (EH1) (for transgenic 
mice) antibody and anti-von Willebbrand factor (vWF) prior to staining with 
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appropriate secondary fluorescent labeled antibodies. Visualization was achieved 
by confocal microscopy (Olympus FV1000-MPE) with the same fluorescence 
intensities during image acquisition.  
 
Detection of Reactive oxygen species (ROS) activity by dihydroethidium (DHE) 
ROS production stimulated by Nef was determined using DHE as a 
fluorescent probe. Confluent HCAEC on 96-well black-walled dishes were 
incubated in conditioned BME medium and 5 µM DHE for 30 min to allow 
intracellular uptake. Cells were washed 3 times with PBS and media replaced 
with phenol-free RPMI. Fluorescence of the oxidized dye was subsequently 
determined at 520 nm (excitation), 605 nm (emission), with 590 nm cutoff on a 
Flex station microplate reader set for maximal detection. 
 
NF-κB p65 silencing in endothelial cells with small interfering RNA 
For RNAi knockdown of the NF-κB subunit p65 gene, we used Ambion’s 
Silencer® Select Custom Designed siRNA against p65 was used as previously 
described (Rajashekhar, Traktuev et al. 2008). Briefly, cells were transfected with 
Lipofectamine 2000 transfection reagent (Invitrogen) and after incubation for 2 
days at 37°C, total cell lysate was used to determine the knockdown of p65 in 
human endothelial cells by Western blotting. 
 
Western Blot analysis 
Proteins were isolated from HCAEC using a cell lysis buffer consisting of 
2.5 mM EDTA, 20 mM Tris pH 7.4, 100 mM NaCl, 1 mM Na3VO4, 1% Triton X-
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100, 10 mM NaF, 1% sodium deoxycholate, 0.1% SDS, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerol phosphate, and 1 tablet/10 ml EDTA-free 
complete protease inhibitor mixture (Sigma Aldrich). Whole-cell extracts prepared 
from HCAEC were resolved in 4–20% bis-Tris polyacrylamide gels 
(Thermoscientific), followed by transfer to nitrocellulose membranes. Membranes 
were probed with primary Abs at suggested concentrations. Proteins were 
visualized by incubation with peroxidase-coupled secondary Abs in the presence 
of LumiGlo reagent while exposing in a Bio-Rad Chemidoc XRS/HQ (Bio-Rad, 
Hercules, CA).  
 
Monitoring mitochondrial function by JC-1 Dye-Mitchondrial Membrane Potential 
Probe 
HCAEC were stained with 2 µg/ml JC-1 dye (Life Technologies) at 24 h 
post Nef transfection. Briefly, JC-1 was dissolved in DMSO and Nef-transfected 
HCAECs were stained for 30 min at 37°C. The medium was replaced with PBS 
before the plate reading. Red fluorescence was determined at 455 nm 
(excitation), 590 nm (emission), with 590 nm cutoff on a Flex station set for 
maximal detection, whereas green fluorescence was determined at 485 nm 
(excitation), 538 nm (emission), with 530 nm cutoff. The ratio of red/green was 
determined as a measurement of mitochondrial depolarization.   
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Detection of Nef in PBMCs 
PBMC were isolated from peripheral blood of HIV patients and uninfected 
controls by standard Ficoll purification. Cells were fixed with 4% PFA for 5 
minutes at RT and permeablized with 0.01% Triton in PBS for 20 min at 4°C. 
Cells were stained with Nef or IgG controls (in some cases, cells were co-stained 
with CD4 T cell marker). The percentage of Nef positive cells was determined 
based on IgG controls.  
 
B cells isolation from PBMCs 
Ten million PBMCs were stained with 10ul PE-conjugated CD19 B cell 
marker, followed by incubating with anti-PE microbeads (Miltenyi). The cells were 
then transferred to the column for magnetic separation step. After washing with 
rinsing buffer, the cells bound in the column represented CD19 positive cells, 
while the elute contained CD19 negative cells. The purity of selected cells from 
this aasay was up to 95%. 
 
Data acquisition and statistical analysis 
MCP-1 production and apoptosis data were both expressed as fold 
increase normalized to controls (mock-transfected cells etc). Data are expressed 
as mean ±SD for each group performed in triplicate and repeated at least three 
times. Shapiro–Wilk test was used to test for normality distribution (n=6). With 
normal distribution, all comparisons were made using parametric ANOVA and 
student’s t test. On some occasions, Welch’s correction was used when the 
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variances were different.  With abnormal distribution, Kruskal-Wallis non-
parametric ANOVA was used. A p value < 0.05 (marked as *) was considered 
statistically significant, and p < 0.01 (marked as **) highly significant.  
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RESULTS 
Part I: HIV Nef causes endothelial activation and dysfunction 
1.1 HIV induces endothelial MCP-1 production and cell death 
In viremic HIV patients, HIV envelope protein gp120 and transcription 
activator Tat are believed to mediate activation of vascular endothelium leading 
to endothelial dysfunction resulting in pulmonary hypertension and 
cardiovascular diseases. However, the role of intracellular proteins such as Nef, 
has been not addressed in cardiovascular diseases. To distinguish between 
effects of cellular Nef and specifically, soluble Tat or HIV-induced cytokine 
release, I asked whether direct contact between T cells and endothelial cells is 
required for endothelial activation. To address this question, I used a transwell 
filter system, which allowed comparison of direct versus cellular contact with 
indirect contact between HIV-infected Jurkat T cells and endothelial cells (Figure 
6A and 6B). In this system, the bottom wells with human coronary artery 
endothelial cells (HCAEC) were either in direct contact with HIV- 
infected/uninfected Jurkat cells or separated by a semi-permeable membrane. As 
shown in Figures 7 and 8, HIV-infected Jurkat cells significantly increased 
endothelial MCP-1 production and apoptosis when in direct contact, whereas 
when HIV-infected Jurkat cells separated from the endothelial monolayer 
exhibited minimal effect. We detected only very minor MCP-1 release from HIV-
infected Jurkat cells alone (Figure 7), suggesting that the observed increased 
MCP-1 production occurred from endothelial cells but not Jurkat cells. As HIV  
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Figure 6: A transwell system  
 
A transwell filter system was used to determine the effects of uninfected or HIV 
infected Jurkat T cells on endothelial MCP-1 release and apoptosis either in 
direct cellular contact (A) or separated by the semi-permeable membrane filter 
(B). 
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Figure 7: HIV-infected Jurkat cells but not acellular HIV virus cause 
endothelial activation  
Endothelial cells were co-cultured in direct or indirect contact with HIV-infected 
Jurkat cells with HCAEC alone (EC), HCAEC in direct contact with uninfected 
Jurkat cells (EC + Jurkat), EC in indirect contact with infected Jurkat cells (EC + 
HIV) or HCAEC in direct contact with infected Jurkat cells (EC + HIV-Jurkat). 
MCP-1 release from HIV infected Jurkat cells was also included (HIV-Jurkat). 
MCP-1 release was analyzed by ELISA. Data were expressed as fold increase in  
MCP-1 production, normalized to mock controls (N=6. *P<0.05, and **P<0.01). 
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Figure 8: HIV-infected Jurkat cells but not acellular HIV virus cause 
endothelial cell death 
A.  HCAEC were co-cultured in direct or indirect contact with HIV-infected Jurkat 
cells (EC), in direct contact with uninfected Jurkat cells (EC + Jurkat), in indirect 
contact with infected Jurkat cells (EC + HIV) or in direct contact with infected 
Jurkat cells (EC + HIV-Jurkat); endothelial apoptosis was determined by TUNEL 
assay.  The cells were then gated for endothelial cells depending on the cell 
sizes by FACS, and only endothelial cells were analyzed for apoptosis 
expression. The “TUNEL” gate was determined by controls from apoptosis kit. B. 
The relative endothelial apoptosis levels. Data were expressed as fold apoptosis, 
normalized to mock controls (N=6. *P<0.05, and **P<0.01). 
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virions containing envelope protein gp120 and soluble Tat or cytokines released 
from infected T cells are able to pass the filter and move freely in the 
supernatant, this finding suggests that a cellular HIV protein in infected T cells or 
a protein induced by HIV causes endothelial MCP-1 production and cell death. 
 
1.2 HIV Nef is necessary for endothelial activation and cell death 
Since HIV gp120 and Tat protein were ruled out by our transwell system, 
HIV early protein, attention was drawn to Nef because of its traits. To specifically 
determine the involvement of Nef in these direct contact dependent effects, we 
employed the same virus titered wild type and Nef-deleted HIV-infected Jurkat 
cells to co-culture with HCAEC. Jurkat cells was infected with wild-type and Nef 
deleted HIV NL4.3 separately, and the virus titers were shown to be queiovalent 
the same in both infected cells at day 9 (Figure 9). Jurkat cells infected with Nef 
deleted HIV induced a much weaker endothelial MCP-1 production (Figure 10A) 
and apoptosis (Figure 10B) in comparison to WT HIV, indicating that Nef protein 
is necessary for HIV-induced endothelial cell death and activation.  
To further analyze whether Nef protein causes endothelial activation and 
dysfunction, we transfected Nef expressing plasmid into Jurkat cells and 
cocultured these cells with HCAEC for 24 h (Figure 11A). Indeed, Nef-Jurkat 
cells induced both endothelial MCP-1 production and cell death (Figure 12A and 
12B). To confirm these Nef dependent activities also apply to monocytes, we 
transfected Nef plasmid into monocytic cell line THP1 cells. Similar to Jurkat cells  
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Figure 9: virus titer determination of ΔNef HIV and WT HIV in Jurkat cells.  
Both WT HIV and ΔNef HIV production reach peak viral production on day 8 or 9 
post infection (dpi) with Jurkat cells. 
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Figure 10:  Nef is necessary for HIV-induced endothelial MCP-1 production 
and cell death 
MCP-1 release (A) and apoptosis (B) in endothelial cells were determined after 
co-culture of endothelial cells with uninfected Jurkat cells (mock), HIV-infected 
Jurkat cells (WT HIV) or Nef deleted HIV-infected Jurkat cells (ΔNef HIV). Data 
were expressed as fold MCP-1 production and apoptosis, normalized to mock 
controls (N=6. *P<0.05, and **P<0.01). 
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Figure 11: The demonstration of Nef transfections. 
(A) Plasmid expressing Nef cDNA was either transfected into Jurkat cells/THP-1 
cells and co-cultured with HCAEC to allow Nef protein transfers to HCAEC (A).  
(B) Alternatively the Nef expressing plasmid was directly transfected into 
HCAEC.  Endothelial cells were measured for or directed transfected to HCAEC 
(B), followed by endothelial apoptosis, and MCP-1 release detection was 
assayed for the transfected cultures. 
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Figure 12: Nef-Jurkat T cells induce endothelial MCP-1 production and cell 
death 
Endothelial MCP-1 production (A) and apoptosis (B) were determined in HCAEC 
alone (EC) or after 24 h coculture with cDNA (Jurkat + EC) or Nef transfected 
Jurkat cells (Jurkat+ Nef + EC). Data were expressed as fold MCP-1 production 
and apoptosis, normalized to mock controls (N=6. *P<0.05, and **P<0.01). 
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Nef dependent increase in MCP-1 production and apoptosis were observed in 
THP-1 cells co-cultured with HCAEC (Figure 13A and 13B).  
 
1.3 HIV Nef is sufficient to cause endothelial activation and cell death 
Next, we questioned if Nef-Jurkat/THP-1 cells induced endothelial 
activation and dysfunction is due to Nef protein triggering cell membrane 
dysfunction or the outcome from the direct effect of Nef protein. We transfected 
Nef into HCAEC (Figure 11B) and measured endothelial MCP-1 release (Figure 
14A), apoptosis (Figure 14B) and ROS formation (Figure 14C). Each was 
significantly increased after 24 h transfection with Nef expressing cells as 
compared to the pcDNA3 controls. Src homology-3 (SH3) domain binding site of 
Nef is essential for many functions in T cells (Manninen, Hiipakka et al. 1998; 
Foti, Cartier et al. 1999). To address the role of this binding site for Nef functions 
in endothelial cells, we also transfected HCAEC with SH3 domain mutated Nef. 
As shown in Fig. 13A-C, the SH3 binding site in Nef is essential for endothelial 
MCP-1 production, apoptosis induction and ROS formation. As ROS has been 
shown to cause vascular leakage, we employed an in vitro vascular permeability 
assay to detect if Nef could increase vascular permeability. Indeed, as shown in 
Figure 15A-C, Nef destroyed the endothelial monolayer and induced HCAEC 
permeability after 24 h post transfection (Figure 15D). In addition, endothelial 
cells transfected with increasing Nef-cDNA amounts display a Nef concentration-
dependent increase (as determined by a Nef-specific ELISA, 
Immunodiangostics) in apoptosis  
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Figure 13: Nef-moncytes THP1 cells induce endothelial MCP-1 production 
and cell death 
Endothelial MCP-1 production (A) and apoptosis (B) were determined in HCAEC 
alone (EC) or after 24 h coculture with cDNA (THP-1 + EC) or Nef transfected 
THP-1 cells (THP-1+ Nef + EC). Data were expressed as fold MCP-1 production 
and apoptosis, normalized to mock controls (N=6. *P<0.05, and **P<0.01). 
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Figure 14. Nef is sufficient to induce endothelial activation and dysfunction.  
A-C. Endothelial MCP-1 release (A), apoptosis (B) and ROS formation (C) were 
determined in endothelial cells transfected with cDNA (EC only), WT Nef (Nef) or 
SH3 binding site mutated Nef (NefΔSH3) after 24 h. Data were expressed as fold 
MCP-1 production and apoptosis, normalized to mock controls (N=6. *P<0.05, 
and **P<0.01). 
  
  70 
 
  
A. No growth factors                 B. pcDNA3 transfected              C. Nef transfected 
 
D. 
  71 
Figure 15: Nef increases HCAEC permeability. 
A-C. Control cDNA or Nef was transfected to HCAEC monolayer in transwells. 
HCAEC vascular permeability was measure after 24 h post-transfection. Basal 
medium treated HCAEC was included as a positive control. D. HCAEC 
permeability was determined by flex station. Data represent mean ±SD from 3 
separate experiments in which measurements were made in triplicate. *P<0.05, 
and **P<0.01.  
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Figure 16: Linear correlation between Nef protein concentration and 
endothelial apoptosis   
Increasing amounts of plasmid expressing HCAEC were transfected with Nef 
plasmid for 24 hrs and concentrations of Nef were measured by ELISA.  The 
measured levels of Nef were then correlated with apoptosis as determined by 
TUNEL-FACS.   
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(Figure 16). In addition, Nef transfected HCAEC displayed increased 
mitochondrial dysfunction and elevated cleaved caspase 3 levels (Figure 17A 
and 17B). There was also a significant linear correlation between intracellular Nef 
concentrations and endothelial MCP-1 production (P= 0.045; Figure 18). These 
data demonstrate that Nef is necessary for HIV-infected T cells to elicit apoptosis 
in HCAEC and sufficient to cause HCAEC activation and increased permeability. 
Importantly, correlation between intracellular Nef concentrations with apoptosis is 
a first step in linking the presence of Nef with pathology. 
 
Part II: Nef mediates its own transfer from T cells to endothelial cells 
2.1 Nef enhances the formation of nanotubes from Jurkat cells to 
endothelial cells.  
Nef protein, but not virus, has been shown to be transferred to HIV-
uninfected bystander cells (Muratori, Cavallin et al. 2009); therefore, we tested 
whether Nef protein could be transferred to endothelial cells by direct contact. To 
achieve this, we labeled Nef or control cDNA transfected Jurkat cells with live 
dye (Vybrant DIO), then co-cultured them with HCAEC and determined live dye 
transfer from Jurkat cells to HCAEC. After 24 hours co-culture, Nef transfected 
Jurkat cells transferred significantly more dye into HCAEC (Figure 19A, 
predominately in perinuclear regions) in comparison to cDNA transfected Jurkat 
cells (Figure 19B). To determine how Nef induced live-dye transfer, we again 
employed the transwell filter system to distinguish between direct contact  
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Figure 17: Nef protein causes endothelial dysfunction. 
A. Mitochondria membrane potentials in endothelial were measured  tested after 
24 h post Nef transfection by the JC-1 staining kit according to the 
manufacturer’s instructions. B. Caspase 3 activity in endothelial cells was tested 
at 24 h post Nef transfection using a caspase 3 kit according to the 
manufacturer’s instructions. Data represent mean ±SD from 3 separate 
experiments in which measurements were made in triplicate. *P<0.05, and 
**P<0.01.  
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Figure 18: Correlation between intracellular Nef concentrations with 
endothelial MCP-1 production 
HCAEC were transfected with Nef expressing plasmid. 24 hrs after transfection 
concentrations of Nef and correlated with endothelial MCP-1 production were 
measured by ELISA, which was also determined by ELISA assay.  
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Figure 19: Nef enhances live dye transfer between cells only when in direct 
contact. 
A-B. Live dye(green) transfer from cDNA transfected Jurkat cells (A) or Nef-
transfected Jurkat cells (B) to endothelial cells after 24 h coculture. Endothelial 
cells (red) were stained by phalloidin. C. Live dye stained Nef or control vector 
transfected Jurkat cells were cocultured with HCAEC either in direct contact, or 
separated by transwell membranes for varying time points. Percentage of live 
dye transfer was determined and quantified by confocal microscopy. The fold dye 
transfer was normalized to cDNA controls for each condition. B is the 
represnatative figure form direct control experiments, which were quantified in C.  
Scale bars represent 10 µm. 
  
  81 
(nanotube formation) mediated and indirect contact (exosome formation) 
transfer. Indeed, we observed that direct but not indirect contact mediated live 
dye transfer relatively early after 8 hours (Figure 19C). We also found that Nef-
transfected Jurkat cells formed significantly more nanotubes to HCAEC 
compared to cDNA-transfected Jurkat cells (Figure 20A, arrow and Figure 20B), 
which also displayed perinuclear live dye (Figure 20A, arrowheads). These 
studies indicate that Nef can promote cytosol exchange and possibly propel its 
own transfer possibly through nanotubes. 
 
The intracellular membrane bound Nef protein reportedly initiates its own 
transfer between blood cells in a process most likely mediated by nanotubes 
(Rudnicka, Feldmann et al. 2009; Rudnicka and Schwartz 2009). However, the 
mechanism of Nef transfer to target tissue cells including vascular endothelial 
cells has not been addressed yet. Therefore, we tested the ability of Nef to be 
transferred from Nef-transfected Jurkat T cells to endothelial cells. Transfected 
Jurkat cells were co-cultured with HCAEC prior to fixation/labeling with Nef mAB 
EH1. After 24 h of co-culture with Nef-transfected T cells, 19.4% of HCAEC were 
positive for Nef compared to only 2% for mock control via FACS analysis (Figure 
21A), demonstrating the ability of Nef to be transferred from Jurkat cells to 
bystander endothelial cells. Furthermore, as shown in Figure 20B endothelial 
cells are positive for Nef after 24 hr exposure with Nef transfected Jurkat cells as 
determined by confocal microscopy.  
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Figure 20: Nef protein induced nanotube formation between Jurkat cells to 
endothelial cells. 
A. Live dye stained Nef-Jurkat cells formed more conduit-like nanotubes between 
Jurkat cells and endothelial cells compared to cDNA Jurkat cells. B. 
Quantification of nanotubes formation in Nef Jurkat cells or cDNA Jurkat cells.  
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Figure 21. Nef transfer to HCAEC. 
A: Nef transfected T cells were cocultured with HCAEC for varying time 
points,and HCAEC  were stained for Nef expression to determine the timecourse 
of Nef transfer from T cells to endothelial cells. Endothelial cells were washed 
with PBS to ensure no adhesion of T cells. Any remaining T cells were gated 
from endothelial cells by FACS based on forward scatter and side scatter 
profiles. Percentage of Nef+EC was determined after subtraction of background 
cDNA signal. ND represents undetectable Nef B:Nef transfer to HCEAC after 
24hr coculture. Endothelial cells were stained with phalloidin (red) and Nef 
(green).  The right corner insert indicates Nef accumulation in HCAEC without an 
overlay. Original magnification, X60. Scale bars represent 10µm. 
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Together, these data suggest that Nef protein induces nanotube structure 
formation from Jurkat cells to endothelial cells, and these structures are central 
for Nef transfer between cells.  
 
2.2 Nef protein can be detected in the endothelium of in vivo HIV models. 
To access the potential relevance of Nef protein in coronary endothelial 
cells in in vivo models, I first used transgenic mice in which Nef-GFP was 
expressed under  
the regulatory sequences of the human CD4 gene, thereby resulting in Nef 
expression in CD4+ T cells and monocytes. Using double staining with anti-Nef 
and endothelial specific antibodies, GFP signal can be demonstrated in coronary 
vessels of CD4-Nef-GFP transgenic mice by confocal microscopy (arrows, Figure 
22B-22C) but not in single CD4-GFP Tg control mice (Figure 22A).  We also 
confirmed that primary mouse T cells were isolated from either CD4-Nef-GFP or 
CD4-GFP transgenic mice cocultured with HCAEC for 24 h, demonstrated more 
GFP signal transfer from Nef-expessing primary T cells to HCAEC ex vivo, 
system by flow cytometry (17% v.s 3%; Figure 23). We then extended these 
results by using a chimeric simian immunodeficiency virus (SIV) expressing HIV 
Nef (SHIV Nef) macaque model. In this model, we detected Nef in coronary 
vessels (Figure 24B-24C); vWF co-staining confirmed the presence of Nef in the 
endothelial lining (Figure 24C, arrow, yellow overlay). Together these data 
provide in vivo evidence that Nef protein can target endothelial cells within the 
vascular system.  
C
. 
D
. 
  87 
   
C.  C. BA. B. C. A. 
  88 
Figure 22: Nef induced GFP transferred from CD4+ cells to endothelial cells 
in Nef transgenic mice 
A-C. Heart sections of single CD4-GFP (A) and double CD4-Nef and GFP (B, C) 
transgenic mice (N=3; at least 4 pictures/slide) were double stained with GFP 
antibody (green, white arrows) and the endothelial marker vWF (red). Shown is 
Nef within the endothelial lining (arrows). Original magnification, X 60. Scale bars 
represent 100 µm. 
  
  89 
 
  
100 101 102 103 104
gfp FITC
na120427.006
R4
100 101 102 103 104
gfp FITC
na120427.007
R4
100 101 102 103 104
CD4 APC
na120427.006
R2
100 101 102 103 104
CD4 APC
na120427.007
R2
CD4 
GFP 
 
 
 
 
  
  
  
  
GFP 3% GFP 12% 
Area 1 Area 1 
         CD4.GFP Mouse                      CD4.Nef.GFP mouse 
A. 
B. 
  90 
Figure 23: More GFP were transferred from CD4+ primary cells to HCAEC 
with Nef present. 
CD4+ primary cells from either GFP mice or Nef.GFP mice  were cocultured with 
HCAEC for 24 hours. CD4 negative HCAEC were sorted through flow cytometry 
(A, area 1), and then stained with anti-GFP antibody(B).  
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Figure 24: Nef can be detected in SIV-hNef macaque models. 
Macaque heart sections (N=5; at least 4 pictures/slide) were double stained with 
IgG control (A) or Nef (B, C, red) and the endothelial marker vWF (green). Shown 
are cells double positive for Nef and vWF in coronary arteries (arrow). Original 
magnification, X 60. Scale bars represent 100 µm. 
 
  
  93 
2.3 Nef protein can be detected in blood cells isolated from HIV positive 
individuals  
Antiretroviral therapy reduces virion production but not Nef gene 
expression. It is possible that these adverse effects of Nef may persist even in 
patients receiving ART. If so, then the persistence of Nef-positive cells during 
ART might contribute to the higher risk of non-AIDS complications observed 
despite ART. We therefore performed a preliminary investigation to assess the 
detection of Nef-positive circulating cells from both ART-untreated and treated 
HIV-infected patients.  PBMCs were isolated from HIV-infected patients and 
uninfected controls by standard Ficoll purification. We found a high mean (SD) 
number of PBMCs from HIV-infected untreated viremic patients that stained 
positive for Nef (Figure 25, Table 2). Of note, Nef dissemination did not correlate 
with viral titers (r = 0.0677; p= 0.86, Figure 26), and one of the HIV patients 
exhibited very low Nef dissemination in PBMC, even though viral titers were high 
(Table 2, patient 8).  We confirmed these results in 4 of the samples using a 
commercially available Nef antibody (3D12, Abcam), which recognizes a different 
epitope, and observed similar Nef staining (EH1: 15.68 ± 3.98%; 3D12: 14.35 ± 
5.139%; p=0.84, n=4) (Figure 27). In addition, we further detected not only Nef 
expression in patients PBMCs, but also nanotubes formation between cells by 
confocal microscopy (Figure 28). Surprisingly, Nef is also detectable in ART 
treated patients with undetectable viral loads (Table 2, patient 10-13). The 
unexpectedly high levels of Nef positive PBMCs cannot be explained by direct  
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Figure 25: Nef is detectable in PBMCs from HIV patients with/without ART.  
FACS analysis of Nef expression in PBMC from untreated (A, frozen samples) 
and virologically suppressive ART treated (C, fresh samples) HIV patients. To 
assure specificity of Nef staining, we included PBMC from healthy donors and 
stained for Nef in parallel (“matched”) with patient derived PBMC (B and D). 
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CD4+ 
count 
(cells/ul)  
Viral load 
(RNA 
copies/ml)  
Nef %(of total  
PBMC )  
ART duration 
(weeks) 
Pooled Uninfected 
ctrl N/A  N/A  0.09  N/A 
Patient 1  365  5700  7.78  N/A 
Patient 2  797  8400  8.66  N/A 
Patient 3  413  1490  12.84  N/A 
Patient 4  913  47800  11.46  N/A 
Patient 5  315  13000  8.04  N/A 
Patient 6  386  5600  24.9  N/A 
Patient 7  593  100000  25.72  N/A 
Patient 8  321  85800  0.02  N/A 
Patient 9 503  35,000  8.02  N/A 
Patient 10  234  <50  1.09  32  
Patient 11  254  <50  1.41  48  
Patient 12  205  <50  1.23  16  
Patient 13  855  <50  0.95  780  
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Table 2: Nef is detectable in PBMCs from HIV patients with/without ART.  
Percentage of Nef+ PBMCs with clinical parameters in patients without and with 
(orange box) ART. 
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Figure 26:  Nef distribution does not correlate with viral load. 
Pearson correlation between viral load and Nef distribution in PBMCs. 
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Figure 27: validation of EH1 monoclonal antibody 
Comparison of 2 anti-NEF monoclonal antibodies (Eh1and Abcam) which are 
directed against unrelated epitopes 
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Figure 28: Nef protein is present in blood cells of HIV patients not on 
antiviral therapy.  
A-B. PBMC from untreated HIV patients (N=3) were stained for Nef (red). 
Matched healthy control (C and D) and untreated patient with IgG control 
antibodies (E and F) were also included. Original magnification, X 60. Scale bars 
represent 5 µm in A and B. Scale bars in the inset of C-F represents 10 µm. 
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HIV infection of cells. In fact, Nef antibody staining was most prominent in non-
CD4-positive cells (Figure 29A). Moreover, when we separated B cells from 
whole patient PBMCs using the Miltenyi anti-PE multisort kit and CD19 antibody 
and stained for Nef, almost 50% of Nef positive cells appear to be B cells (Figure 
29B). 
To test if Nef from blood derived mononuclear cells could also transfer to 
endothelial cells, we cocultured human umbilical cord vein endothelial cells 
(HUVEC) with PBMCs from viremic untreated HIV-infected patients for 24 hours. 
As shown in Figure 30, this experiment resulted in strongly (arrow) and less 
strongly (arrow head) Nef-positive endothelial cells, which is likely due to different 
levels of Nef transfer. Of note, these endothelial cells are not leukocytes based 
on characteristic cytoskeletal morphology as determined by staining with 
phalloidin-Cy5. 
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A. 
B. 
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Figure 29: Nef is prominent present in CD4- cells. 
A. Determination of CD4+ and CD4- Nef-positive PBMCs by double staining and 
FACS. Data represent mean ±SD from 3 separate experiments in which 
measurements were made in triplicate. B. Comparison of Nef-positive B cell 
versus non B cell populations after immune-magnetobead based separation. 
Data represent mean ±SD from 3 separate experiments in which measurements 
were made in triplicate. 
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Figure 30: Nef can be transferred from HIV-PBMCs to endothelial cells ex 
vivo. 
Nef staining of HUVEC after 24 hours in contact with PBMCs from HIV patients 
shown as Nef stain only (green) or as overlay with red phalloidin staining 
depicting endothelial-like cytoskeletal actin staining. 
  
  109 
Part III: Signal transduction analysis of Nef induced endothelial activation 
and dysfunction. 
We next aimed to specifically analyze the signal transduction pathway of 
Nef-induced HCAEC activation. First we tested involvement of NF-κB signaling 
for Nef-induced MCP-1 production. Using siRNA to knockdown the p65 subunit 
of NF-κB or the NF-κB inhibitor Ikki (Green, Kim et al. 2012),  we addressed the 
role of NF-κB for Nef-induced chemokine production (Figure 31). Based on 
previous reports linking Nef to reactive oxygen species (ROS) formation 
(Olivetta, Pietraforte et al. 2005), we addressed the role of ROS in Nef-induced 
endothelial dysfunction. Whereas the ROS inhibitor vitamin E derivative Trolox 
(Figure 32) had no effect on Nef-induced MCP-1 production (Figure 34A), Nef-
induced apoptosis in HCAEC was abolished by Trolox (Figure 35). We further 
examined if Nef-induced ROS production and apoptosis is derived from NADPH 
oxidase using the NADPH oxidase inhibitors apocynin and the gp91phox/Nox2 
B-loop peptide (Nox2ds) (Figure 33). Both NADPH inhibitors abolished Nef-
induced ROS production and endothelial apoptosis (Figure 35A). However, NF-
κB inhibition (Ikki) did not reduce Nef-induced endothelial apoptosis, indicating 
that Nef-induced apoptosis does not require NF-κB activation (Figure 34). 
Furthermore, to rule out the possibility that Nef induced endothelial dysfunction is 
due to artificially high Nef concentrations caused by overexpression in 
endothelial cells, we used the Nef co-culture based transfer system as described 
above, in which Nef protein shuttles from Nef transfected Jurkat cells into  
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Figure 31. Nef induced endothelial MCP-1 production is NF-kB dependent. 
Endothelial cells were co-transfected with Nef cDNA and NF-κB p65 siRNA. After 
18 h and 24 h, knock-down of p65 was confirmed by Western blot (Inserts: Lane 
1, control; Lane 2, scrambled siRNA; Lane 3, 18h p65siRNA knock-down; Lane 
4, 24h p65siRNA knock-down). MCP-1 production was tested at 24 h post Nef 
transfection in the supernatant using ELISA. Data were expressed as fold MCP-1 
production, normalized to mock controls. Data represent mean ±SD from 3 
separate experiments in which measurements were made in triplicate. *P<0.05, 
and **P<0.01. 
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Figure 32: Optimize Trolox concentration in ROS inhibition. 
Trolox with different dosage were separately added to Nef cDNA transfected 
HCAEC for 18 h incubation. Detection of intracellular ROS formation was 
assessed with DHE using a Flex station. Data represent mean ±SD from 3 
separate experiments in which measurements were made in triplicate. *P<0.05, 
and **P<0.01. 
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Figure 33: NADPH inhibitors dose determination to block Nef-induced 
intracellular ROS activation in HCAEC.   
Apocynin with different dosage and optimized 10uM Nox2 inhibitor were 
separately added to Nef cDNA transfected HCAEC for 18 h incubation. Detection 
of intracellular ROS formation was assessed with DHE using a Flex station. Data 
represent mean ±SD from 3 separate experiments in which measurements were 
made in triplicate. *P<0.05, and **P<0.01. 
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A. B. 
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Figure 34. Ikki inhibited Nef induced endothelial MCP-1 production. 
(A) Endothelial cells were transfected with Nef expressing plasmid, incubated for 
further 6 hours and treated with apocynin (200nM), trolox (200nM), or IKKi 
(100nM). After additional 18 hours supernatants were analyzed for Nef-induced 
MCP-1 production. (B) Endothelial cells were cocultured with Nef-transfected 
Jurkat cells for 24 h, and then treated with NADPH gp91 specific peptide Nox2 
inhibitor (10uM), apocynin (200nM),  trolox (200nM), or IKKi (100nM) and 
incubated an additional 12 h, then analyzed for Nef-induced MCP-1 production. 
Data were expressed as fold MCP-1 production, normalized to mock controls. 
Data represent mean ±SD from 3 separate experiments in which measurements 
were made in triplicate. *P<0.05, and **P<0.01. 
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A. B. 
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Figure 35. Nef induced endothelial cell death is ROS/NADPH dependent. 
(A) Endothelial cells were transfected with Nef cDNA, incubated for further 6 
hours and treated with NADPH gp91 specific peptide Nox2 inhibitor (10uM), 
apocynin (200nM), trolox (200nM), or IKKi (100nM). After additional 18 hours 
cells, cells were collected or apoptosis TUNEL assay. (B) Endothelial cells were 
cocultured with Nef-transfected Jurkat cells for 24 h, and then treated with 
NADPH gp91 specific peptide Nox2 inhibitor (10uM), apocynin (200nM), trolox 
(200nM), or IKKi (100nM) and incubated an additional 18 h, then analyzed for 
Nef-induced endothelial apoptosis. Data were expressed as fold MCP-1 
production, normalized to mock controls. Data represent mean ±SD from 3 
separate experiments in which measurements were made in triplicate. *P<0.05, 
and **P<0.01. 
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cocultured HCAEC. We demonstrated the same signaling pathways for 
endothelial MCP-1 production and apoptosis in these HCAEC coculture with Nef-
transfected Jurkat cells. We demonstrated the same signaling pathways for 
endothelial MCP-1 production and apoptosis in these HCAEC cocultured with 
Nef-transfected Jurkat cells (Figure 34B and 35B).  Thus, Nef induces endothelial 
MCP-1 through NF-kB pathway while induces endothelial cell death through 
NADPH pathway. 
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DISCUSSION 
Summary of the results 
Nef protein induces its own transfer from T cells and monocytes to 
endothelial cells, which consequently and necessarily induces endothelial cell 
activation, dysfunction, and death. Nef induces apoptosis of endothelial cells 
through an NADPH oxidase- and ROS-dependent mechanism, while Nef-induced 
MCP-1 production is NF-κB dependent. Our findings are in line with the widely 
accepted connection between endothelial dysfunction/oxidative stress and risk of 
cardiovascular events in patients with coronary artery disease in general 
(Heitzer, Schlinzig et al. 2001) and in HIV individuals specifically (Baliga, Chaves 
et al. 2005). Interestingly, Nef was already linked to pulmonary hypertension and 
endothelial endothelial dysfunction (Duffy, Wang et al. 2009; Almodovar, Hsue et 
al. 2011). Our finding of Nef-induced ROS production could explain Nef-induced 
decreased NO levels and ER dysfunctions in pulmonary arteries (Kojda and 
Harrison 1999; Duffy, Wang et al. 2009). Furthermore, our finding of Nef protein 
presence increasing endothelial MCP-1 production concurs with the important 
role of this chemokine in atherosclerosis. This finding is particularly noteworthy in 
light of a link between early atherosclerosis and MCP-1 levels in HIV patients 
(Gosling, Slaymaker et al. 1999; Alonso-Villaverde, Coll et al. 2004), as arterial 
inflammation in HIV patients is a common denominator and associated with a 
circulating marker of monocyte and macrophage activation (Subramanian, 
Tawakol et al. 2012). 
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The next aspect of Nef transfer we investigated was whether Nef protein 
could be also transferred in vivo. We demonstrated a great dissemination of Nef 
protein in PBMCs of HIV-infected individuals that most Nef positive cells were 
CD4- uninfected cells.  We also found not only an unexpected high level of Nef 
expression in HIV-patients without ART, but also a significant levels of Nef-
positive PBMCS in ART treated patients with undetectable HIV RNA viral loads. 
These in vivo findings suggest that Nef protein may be widely transferred from 
HIV-infected cells to uninfected cells, providing a means of pathogenic Nef 
activity even when virus replication is controlled. 
  
Nef protein can be transferred to endothelial cells 
In our tissue culture models, Nef transfection in uninfected Jurkat cells 
was sufficient to stimulate nanotube formation between Jurkat cells and 
endothelial cells. Quantification by FACS analysis revealed that 17% of HCAEC 
had Nef protein transferred to them from Jurkat cells/THP1 cells after 24 hours 
coculture. Our data suggests that the mechanism of Nef protein transfer between 
blood cells and vascular endothelial cells most likely involves nanotube 
formation. Reportedly, using IHC from human tissue many Nef protein 
expressing bystander cells can be found in lymphatic vessels, and under the low 
shear stress conditions in these vessels cellular transfer may be easily mediated 
by nanotube transfer from infected cells (Qiao, He et al. 2006). Under shear 
stress conditions, exosome-mediated transfer would be an alternative 
mechanism for transfer. However, despite previous reports of Nef transfer to 
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bystander cells by Nef-containing exosomes, we did not find evidence of Nef 
transfer through this mechanism. Importantly, we applied a membrane staining 
live dye (Vybrant Dio), which excludes the possibility of Nef transfer via gap 
junction. Nanotube transfer from blood cells to the endothelium is possible 
despite shear stress as T cells and monocytes are in constant close contact to 
vascular endothelium as part of immuno-surveillance. In addition, HIV infection 
itself may cause proinflammatory conditions leading to increased adhesion of 
infected and noninfected Nef carrying T cells and monocytes (Yang, Liu et al. 
2010) and thus enhancement of nanotube formation and Nef transfer. 
As a first proof of principle, we provided the evidence that Nef can be 
transferred into endothelial cells in vivo. We assessed a transgenic approach to 
address Nef protein transfer more specifically by using the regulatory sequences 
of the human CD4 gene to drive Nef expression in a Tg mouse model.  Based on 
our in vitro finding that Nef protein can be readily transferred from infected or 
transfected Jurkat cells to endothelial cells, we anticipated that this model was of 
pathophysiological relevance. Indeed, demonstration of Nef protein in endothelial 
cells (Figure 20) provides further support for the hypothesis that Nef presence in 
endothelial cells can occur in the absence of viral infection. Although “leaky” CD4 
regulatory elements cannot be totally excluded, our Nef staining occurs at a 
relatively high intensity, which is usually not seen in expression caused by leaky 
promoters. Importantly, a “leaky” promoter can be further ruled out by our 
established monkey model of HIV infection, in which macaques were infected 
with SHIV-Nef, an SIV construct containing HIV Nef alleles (Sehgal, 
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Mukhopadhyay et al. 2009; Almodovar, Hsue et al. 2011). In this model 
endothelial location of Nef has already been demonstrated in stenotic pulmonary 
arteries, indicating a role of HIV Nef in pulmonary hypertension. Unfortunately we 
could not include SHIV negative macaque hearts because they were not kept in 
the corresponding study. We looked for commercially available sections but the 
only provider we could identify had discontinued the provision of paraffin 
embedded coronary sections from apes. However, Nef staining in pulmonary 
arteries from SHIV but not healthy macaques had been demonstrated previously 
(Sehgal, Mukhopadhyay et al. 2009). In fact, this IF-based evidence of human 
Nef in HIV-Nef-SIV chimeric virus infected macaques is in confirmation of Nef 
being present in the vascular system. Further confirmation with human tissue 
samples should be addressed in future studies. 
 
Nef protein is detectable in HIV-patients with/without ART 
Unexpected high Nef levels were detected in most HIV naïve patients; 
however, one of the HIV patients exhibited very low Nef dissemination in PBMC, 
even though viral titers were high (Table 2, patient 8). The identification of 
mechanisms underlying this low spreading tendency of Nef, such as the 
possibility of a mutation impairing Nef protein transfer, would be interesting for 
therapeutic targeting of Nef. The unexpectedly high levels of Nef positive PBMCs 
cannot be explained by direct HIV infection of cells. In fact, Nef antibody staining 
was most prominent in non-CD4-positive cells, which is in line with the reported 
ability of Nef protein to be transferred in vitro from infected monocytes and T cells 
  125 
to bystander cells (Figure 27A). Moreover, our finding that almost 50% of Nef 
positive cells appear to be B cells (Figure 27B) is in line with previous in vitro 
studies showing that Nef can be transferred from HIV infected monocytes to B 
cells (Qiao, He et al. 2006). 
Nef is one of the 3 immediate early HIV genes, which are still transcribed 
in HIV-infected cells even in those receiving ART. Interestingly, we also found 
significant levels of Nef-positive PBMCs (mean (SD), 1.17±0.19%, P=0.001 
compared to non-infected controls) in ART treated patients with HIV RNA viral 
loads < 50 copies/ml (Table 2, orange box). This finding could be explained by 
transfer of Nef from infected cells located in lymphatic tissues, a major HIV 
reservoir (Chiueh, Andoh et al. 2005; Hunt 2010). High endothelial venules 
enable lymphocyte circulation between blood and lymph nodes (Mackay, 
Marston et al. 1990) and are most likely in prolonged direct contact with Nef-
containing mononuclear cells (Stolp, Imle et al. 2012). 
 
Nef as the potential targets for HIV-related cardiovascular disease 
To explore potential targets that could interfere with Nef-induced 
endothelial dysfunction we addressed the mechanism of Nef action. First, we 
employed the fact that Nef protein contains a conserved motif with the minimal 
consensus (PxxP) site for SH3-mediated protein-protein interactions. This SH3 
domain was shown previously to be involved in many Nef activities (Foster and 
Garcia 2008). Further, our demonstration that the Nef SH3 binding site plays a 
key role in Nef-induced endothelial apoptosis is in line with previous reports that 
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Nef activates and induces NADPH oxidase (Vilhardt, Plastre et al. 2002; Salmen, 
Colmenares et al. 2010), which may also explain the known impairment of eNOS 
activity and reduced NO bioavailabilty in HIV-related vascular dysfunction (Kline, 
Kleinhenz et al. 2008; Duffy, Wang et al. 2009). Indeed, we observed that Nef 
induces apoptosis of endothelial cells through a NADPH oxidase- and ROS-
dependent mechanism that is independent of NF-κB activation. In this study, we 
included the ROS inhibitor Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid), a water-soluble analog of vitamin E, as a scavenger of O2- (Arts, 
Haenen et al. 2004). Apocynin usually acts as an NADPH oxidase inhibitor, but 
recent results from Heumüller et al. (Heumuller, Wind et al. 2008) suggest that 
apocynin does not inhibit NADPH oxidase in endothelial cells because apocynin 
dimers cannot form without myeloperoxidase (MPO). These results, however, are 
based on cultured HEK293 cells that were transfected to overexpress NADPH 
oxidase isoforms. Other studies have shown the controversial results, that 
apocynin dimers are present in endothelial cells (Johnson, Schillinger et al. 2002) 
and MPO may be transferred into endothelial cells by a cytokeratin 1 pathway 
(Astern, Pendergraft et al. 2007). Other peroxidases in endothelial cells may also 
substitute for MPO. Schlüter et al. (Schluter, Steinbach et al. 2008) have shown 
that Apocynin does not inhibit vascular NADPH-oxidase-dependent superoxide 
formation but does inhibit Rho kinase activity. Recently, Steven J Miller et al 
found that mesenteric arteries in spontaneously hypertensive rats (SHR) (Zhou, 
Pyriochou et al. 2008) and retired breeder Wistar-Kyoto rats (WKY) have in vivo 
hydrogen peroxide concentrations in excess of what was necessary for apocynin-
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mediated inhibition of superoxide production in the Schlüter study (Miller, 
Coppinger et al. 2010).  In contrast, the Nox2ds peptide we used in this study 
specifically inhibits O(2)(•-) production by the vascular isoform of NADPH 
oxidase-Nox2 oxidase, but does not inhibit ROS production by either Nox1- or 
Nox4-oxidase (Csanyi, Cifuentes-Pagano et al. 2011). Because these NADPH 
oxidase- and ROS inhibitors were added early (6 hours) after transfection with 
Nef cDNA followed by determination of MCP-1 release, mitochondrial 
dysfunctions, ROS and apoptosis after 18 hours, we hypothesize that NADPH 
oxidase induces ROS formation, mitochondria dysfunction and apoptosis in 
endothelial cells. Although we could demonstrate mitochondrial dysfunction in 
Nef-induced endothelial cell apoptosis at later time points, early inhibition of 
NADPH oxidase using either pharmacological or biochemical peptide based 
inhibitors strongly suggests that NADPH activation is an essential early step for 
Nef-induced apoptosis by ROS-dependent mitochondrial dysfunction and 
subsequent release of cytochrome c and caspase activation, as was previously 
reported as a mechanism of ROS-dependent apoptosis. The cross talk between 
mitochondria and NADPH oxidases is bidirectional (Dikalov 2011; Dikalov and 
Ungvari 2013). Our proposed scheme suggests that Nef dysregulates endothelial 
mitochondria through inducing ROS and caspase activity. Increasing evidence 
shows that hypertension is associated with an increased mitochondria-derived 
production of ROS in various animal models, including mitochondria increased 
vascular ROS production by resistant mesenteric arteries and aorta (Viel, 
Benkirane et al. 2008; Dikalova, Bikineyeva et al. 2010). Mitochondria-derived 
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ROS is also critical for the central regulation of systemic cardiovascular function 
(Nautiyal, Arnold et al. 2013).  
Given our finding that Nef-induced ROS production is necessary for Nef-
induced endothelial cell death, anti-oxidant supplementation may be an exciting 
and novel means of reducing CVD in this population. In fact, in non-HIV infected 
patients, long-term administration of antioxidant vitamins C and E improved 
coronary and brachial artery endothelial function in patients with coronary artery 
disease, while multivitamin supplementation of HIV positive women during 
pregnancy reduced hypertension (Kinlay, Behrendt et al. 2004; Merchant, 
Msamanga et al. 2005). However, the beneficial effects of antioxidants for CVD 
in the HIV negative population are controversial (Hodis, Mack et al. 2002; 
Riccioni, Frigiola et al. 2012) and further post-data analyses or new studies within 
the HIV positive population would be interesting.  
In previous studies, MCP-1-stimulated migration was described to require 
ROS production in certain cells (Lo, Shih et al. 2005; Habibzadegah-Tari, Byer et 
al. 2006). In our study, we clearly stated that the MCP-1 pathway is independent 
of ROS activation (Figure 36).  We found that NF-κB inhibition but not NADPH or 
ROS inhibition strongly reduced MCP-1 production. We chose MCP-1 production 
in endothelial cells as a readout for proinflammatory endothelial activation and 
dysfunction because it has been linked to cardiovascular diseases in a series of 
human and mouse studies (Ohman, Wright et al. 2010; Liu, Zhang et al. 2012) as 
well as with HIV infection (Alonso-Villaverde, Coll et al. 2004; Eugenin, Gaskill et 
al. 2009) . Recent studies have reported that pharmaceutical MCP-1 inhibitor L-
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enantiomeric RNA oligonucleotide mNOX-E36 (a so-called Spiegelmer) 
successfully blocked MCP-1 during chronic liver inflammation and damage in an 
animal model (Baeck, Wehr et al. 2012). This could also be applied to future 
studies to test if this inhibitor can block Nef induced endothelial MCP-1 
production. In this context, the myriostylation site of Nef itself could be a target 
for drugs which block protein farnesylation. Of note, statins, as HMG-CoA 
reductase inhibitors, are expected to have this function (Stein, Merwood et al. 
2004; Hurlimann, Chenevard et al. 2006). It would be interesting to test whether 
statins are also able to reduce Nef activity, which would provide a rationale to 
apply an already existing cardiovascular protective regimen for HIV infected 
patients regardless of their cholesterol levels. 
 
Alternative ways to inhibit Nef expression 
Instead of inhibiting Nef-induced endothelium activation and dysfunction 
mechanism, an alternative could be the use Nef inhibitors. So far, only a few Nef 
inhibitors have been described, including chemical compounds capable of 
interfering Nef SH3 binding domains (Hiipakka, Huotari et al. 2001; Betzi, 
Restouin et al. 2007) and an Hck activation blocker (Emert-Sedlak, Kodama et al. 
2009). Unfortunately, some inhibitors were either too cytotoxic or only showed 
activity in cellular and biochemistry-based assays.  However, the new 
breakthrough monoclonal single-domain Nef neutralization antibody (anti-Nef 
sdAb) overcomes these problems and it inhibits the positive effect of Nef on virus 
replication in PBMCs (Bouchet, Basmaciogullari et al. 2011).  This antibody is 
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composed of heavy chains only, with a single variable domain (VHH) capable of 
recognizing cognate antigens. The advantage of sdAb is having no requirement 
for disulfide bond formation when targeting of proteins found in reducing cell 
compartments. Therefore, it will be interesting to test if anti-Nef sdAb can block 
Nef-induced endothelial dysfunction in future studies.   
In summary, the main significance of this study is that the HIV Nef protein 
can transfer to endothelial cells where it has dramatic effects, including the 
release of atherosclerotic chemokines, ROS formation, mitochondrial dysfunction 
and apoptosis. Pharmacologic interventional studies are now needed to 
determine the effects of Nef pathway inhibition, in addition to ART, to improve 
endothelial function and reduce the risk of cardiovascular disease in those 
infected with HIV.  
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Figure 36: Nef signaling pathways in HCAEC 
Nef induced endothelial MCP-1 production and apoptosis pathways are shown in 
the above scheme.  
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Future Directions: 
To validate signal transduction target for therapeutical application 
1.  Transgenic Mice Models  
Based on my finding of Nef presents in endothelium from CD4.Nef.GFP 
mice, we could further investigate these transgenic animals. Our collaborator 
(who provided the mice heart sections) had reported that using this transgenic 
approach tissue specific expression of Nef was sufficient to cause AIDS-like 
disease, B and T cell dysfunction, end organ diseases including lymphatic, 
kidney, and pulmonary, cardiac and coronary pathologies. Although coronary 
vascular dysfunction was compromised in these mice (Kay, Yue et al. 2002), the 
significance of these findings for atherosclerotic diseases was not addressed. 
Therefore, we could crossover Nef Tg mice with ApoE gene-deficient mice, an 
established model of atherosclerosis. Importantly, antiretroviral therapy is well 
known to cause hyperlipidemia (Carpentier, Patterson et al. 2005), which is best 
addressed in the widely used ApoE -/- model (Hofker, van Vlijmen et al. 1998; 
Jawien, Nastalek et al. 2004; Koga, Kai et al. 2007). In this model we can further 
address the hypothesis that Nef in CD4 and possibly also in other PBMC as well 
as in arterial vascular endothelial cells combines Nef-induced mononuclear and 
endothelial cell dysfunction to cause and/or enhance atherosclerotic changes. In 
addition to more specifically addressing the role endothelial Nef in 
atherosclerosis, we can generate Tg mice expressing Nef only in endothelial 
cells, under a tetracycline regulated (tetracycline treatment to be stopped to turn 
expression on) endothelial specific tie2 and/or VE-cadherin promoters (Mukai, 
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Rikitake et al. 2006). Again we will backcross these endothelial Nef expressing 
mice into the apopE -/- background. Thus, these transgenic lines can be used for 
assessing targets of Nef signaling in order to intervene in HIV associated 
vascular diseases, starting these studies with a proof of principle Nef transgenic 
signaling mutant (delta SH3) as this mutant was described previously to lead to 
reduced AIDS-like symptoms in comparison with wild type Nef transgenic mice 
(Hanna, Weng et al. 2001). 
 
2. Pilot Study 
As ART reduces virion production but not Nef gene expression, it is 
possible that these adverse effects of Nef may persist even in patients receiving 
ART. If so, then the persistence of Nef-positive cells during ART might contribute 
to the higher risk of non-AIDS complications observed despite ART. In the 
previous experiments (Table 2), we have demonstrated the dissemination of Nef 
in PBMC of HIV patients and its ability to be transferred to endothelial cells 
(Figure 21). Thus, it is important to further quantify the cellular dissemination of 
Nef protein in the blood from HIV patients on ART and its ability to affect the 
vascular system.  We can isolate PBMCs from up to 40 HIV-infected patients and 
uninfected volunteers to determine the amount of Nef protein in their PBMCs by 
using Nef ELISA kit. In the meantime, the Nef protein concentration in each 
patient will be compared to their malondialdehyde (MDA) level, a circulating 
biomarker of oxidative stress (Gerritsen, van Boven et al. 2006) and flow-
mediated dilation (FMD) level of the brachial artery (Abbott, Harkness et al. 
2002), a well-accepted measure of in vivo endothelial function and predictor of 
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CVD. In addition, my data showed that anti-oxidant could block HIV Nef-induced 
endothelial apoptosis. Thus, we could also assess the effects of the antioxidant 
agents N-acetylcysteine (NAC) and the ACE-inhibitor lisinopril on circulating 
MDA levels and FMD in HIV-infected persons receiving virologically suppressive 
ART.  
  
  
  136 
REFERENCES 
Abbott, R. A., M. A. Harkness, et al. (2002). "Correlation of habitual physical 
activity levels with flow-mediated dilation of the brachial artery in 5-10 year 
old children." Atherosclerosis 160(1): 233-239. 
Aiello, R. J., P. A. Bourassa, et al. (1999). "Monocyte chemoattractant protein-1 
accelerates atherosclerosis in apolipoprotein E-deficient mice." 
Arterioscler Thromb Vasc Biol 19(6): 1518-1525. 
Albini, A., R. Soldi, et al. (1996). "The angiogenesis induced by HIV-1 tat protein 
is mediated by the Flk-1/KDR receptor on vascular endothelial cells." Nat 
Med 2(12): 1371-1375. 
Alimonti, J. B., T. B. Ball, et al. (2003). "Mechanisms of CD4+ T lymphocyte cell 
death in human immunodeficiency virus infection and AIDS." J Gen Virol 
84(Pt 7): 1649-1661. 
Almodovar, S., P. Y. Hsue, et al. (2011). "Pathogenesis of HIV-associated 
pulmonary hypertension: potential role of HIV-1 Nef." Proc Am Thorac Soc 
8(3): 308-312. 
Alonso-Villaverde, C., B. Coll, et al. (2004). "Atherosclerosis in patients infected 
with HIV is influenced by a mutant monocyte chemoattractant protein-1 
allele." Circulation 110(15): 2204-2209. 
Ambrose, J. A. and R. S. Barua (2004). "The pathophysiology of cigarette 
smoking and cardiovascular disease: an update." J Am Coll Cardiol 
43(10): 1731-1737. 
  137 
Arts, M. J., G. R. Haenen, et al. (2004). "Antioxidant capacity of reaction products 
limits the applicability of the Trolox Equivalent Antioxidant Capacity 
(TEAC) assay." Food Chem Toxicol 42(1): 45-49. 
Astern, J. M., W. F. Pendergraft, 3rd, et al. (2007). "Myeloperoxidase interacts 
with endothelial cell-surface cytokeratin 1 and modulates bradykinin 
production by the plasma Kallikrein-Kinin system." Am J Pathol 171(1): 
349-360. 
Baeck, C., A. Wehr, et al. (2012). "Pharmacological inhibition of the chemokine 
CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis 
in chronic hepatic injury." Gut 61(3): 416-426. 
Baliga, R. S., A. A. Chaves, et al. (2005). "AIDS-related vasculopathy: evidence 
for oxidative and inflammatory pathways in murine and human AIDS." Am 
J Physiol Heart Circ Physiol 289(4): H1373-1380. 
Barillari, G., C. Sgadari, et al. (1999). "The Tat protein of human 
immunodeficiency virus type-1 promotes vascular cell growth and 
locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and 
by mobilizing sequestered basic fibroblast growth factor." Blood 94(2): 
663-672. 
Bartlett, J. G. (1990). "Management of patients with asymptomatic HIV infection." 
Md Med J 39(2): 150-155. 
Betzi, S., A. Restouin, et al. (2007). "Protein protein interaction inhibition (2P2I) 
combining high throughput and virtual screening: Application to the HIV-1 
Nef protein." Proc Natl Acad Sci U S A 104(49): 19256-19261. 
  138 
Blagoveshchenskaya, A. D., L. Thomas, et al. (2002). "HIV-1 Nef downregulates 
MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway." Cell 
111(6): 853-866. 
Blankson, J. N. (2010). "Control of HIV-1 replication in elite suppressors." Discov 
Med 9(46): 261-266. 
Bouchet, J., S. E. Basmaciogullari, et al. (2011). "Inhibition of the Nef regulatory 
protein of HIV-1 by a single-domain antibody." Blood 117(13): 3559-3568. 
Bour, S. and K. Strebel (1996). "The human immunodeficiency virus (HIV) type 2 
envelope protein is a functional complement to HIV type 1 Vpu that 
enhances particle release of heterologous retroviruses." J Virol 70(12): 
8285-8300. 
Brownlee, M. (2001). "Biochemistry and molecular cell biology of diabetic 
complications." Nature 414(6865): 813-820. 
Bukrinsky, M. and A. Adzhubei (1999). "Viral protein R of HIV-1." Rev Med Virol 
9(1): 39-49. 
Carpentier, A., B. W. Patterson, et al. (2005). "Mechanism of highly active anti-
retroviral therapy-induced hyperlipidemia in HIV-infected individuals." 
Atherosclerosis 178(1): 165-172. 
Carr, A. and D. Ory (2006). "Does HIV cause cardiovascular disease?" PLoS 
Med 3(11): e496. 
Cerboni, C., F. Neri, et al. (2007). "Human immunodeficiency virus 1 Nef protein 
downmodulates the ligands of the activating receptor NKG2D and inhibits 
natural killer cell-mediated cytotoxicity." J Gen Virol 88(Pt 1): 242-250. 
  139 
Chan, D. C. and P. S. Kim (1998). "HIV entry and its inhibition." Cell 93(5): 681-
684. 
Chaudhry, A., S. R. Das, et al. (2005). "The Nef protein of HIV-1 induces loss of 
cell surface costimulatory molecules CD80 and CD86 in APCs." J 
Immunol 175(7): 4566-4574. 
Chaudhuri, R., O. W. Lindwasser, et al. (2007). "Downregulation of CD4 by 
human immunodeficiency virus type 1 Nef is dependent on clathrin and 
involves direct interaction of Nef with the AP2 clathrin adaptor." J Virol 
81(8): 3877-3890. 
Cheung, M. C., L. Pantanowitz, et al. (2005). "AIDS-related malignancies: 
emerging challenges in the era of highly active antiretroviral therapy." 
Oncologist 10(6): 412-426. 
Chi, D., J. Henry, et al. (2000). "The effects of HIV infection on endothelial 
function." Endothelium 7(4): 223-242. 
Chiueh, C. C., T. Andoh, et al. (2005). "Roles of thioredoxin in nitric oxide-
dependent preconditioning-induced tolerance against MPTP neurotoxin." 
Toxicol Appl Pharmacol 207(2 Suppl): 96-102. 
Cimarelli, A., S. Sandin, et al. (2000). "Basic residues in human 
immunodeficiency virus type 1 nucleocapsid promote virion assembly via 
interaction with RNA." J Virol 74(7): 3046-3057. 
Cohen, M. S., N. Hellmann, et al. (2008). "The spread, treatment, and prevention 
of HIV-1: evolution of a global pandemic." J Clin Invest 118(4): 1244-1254. 
  140 
Cooper, E. R., R. P. Nugent, et al. (1996). "After AIDS clinical trial 076: the 
changing pattern of zidovudine use during pregnancy, and the subsequent 
reduction in the vertical transmission of human immunodeficiency virus in 
a cohort of infected women and their infants. Women and Infants 
Transmission Study Group." J Infect Dis 174(6): 1207-1211. 
Craig, W. Y., G. E. Palomaki, et al. (1989). "Cigarette smoking and serum lipid 
and lipoprotein concentrations: an analysis of published data." BMJ 
298(6676): 784-788. 
Csanyi, G., E. Cifuentes-Pagano, et al. (2011). "Nox2 B-loop peptide, Nox2ds, 
specifically inhibits the NADPH oxidase Nox2." Free Radic Biol Med 51(6): 
1116-1125. 
Cybulsky, M. I., K. Iiyama, et al. (2001). "A major role for VCAM-1, but not ICAM-
1, in early atherosclerosis." J Clin Invest 107(10): 1255-1262. 
Das, S. R. and S. Jameel (2005). "Biology of the HIV Nef protein." Indian J Med 
Res 121(4): 315-332. 
Deanfield, J., A. Donald, et al. (2005). "Endothelial function and dysfunction. Part 
I: Methodological issues for assessment in the different vascular beds: a 
statement by the Working Group on Endothelin and Endothelial Factors of 
the European Society of Hypertension." J Hypertens 23(1): 7-17. 
Debaisieux, S., F. Rayne, et al. (2012). "The ins and outs of HIV-1 Tat." Traffic 
13(3): 355-363. 
Diaz, P. T., E. R. King, et al. (2000). "HIV infection increases susceptibility to 
smoking-induced emphysema." Chest 117(5 Suppl 1): 285S. 
  141 
Dikalov, S. (2011). "Cross talk between mitochondria and NADPH oxidases." 
Free Radic Biol Med 51(7): 1289-1301. 
Dikalov, S. I. and Z. Ungvari (2013). "Role of mitochondrial oxidative stress in 
hypertension." Am J Physiol Heart Circ Physiol 305(10): H1417-1427. 
Dikalova, A. E., A. T. Bikineyeva, et al. (2010). "Therapeutic targeting of 
mitochondrial superoxide in hypertension." Circ Res 107(1): 106-116. 
Djordjevic, J. T., S. D. Schibeci, et al. (2004). "HIV type 1 Nef increases the 
association of T cell receptor (TCR)-signaling molecules with T cell rafts 
and promotes activation-induced raft fusion." AIDS Res Hum Retroviruses 
20(5): 547-555. 
Duffy, P., X. Wang, et al. (2009). "HIV Nef protein causes endothelial dysfunction 
in porcine pulmonary arteries and human pulmonary artery endothelial 
cells." J Surg Res 156(2): 257-264. 
Duffy, P., X. Wang, et al. (2009). "HIV Nef Protein Causes Endothelial 
Dysfunction in Porcine Pulmonary Arteries and Human Pulmonary Artery 
Endothelial Cells." J Surg Res. 
Emert-Sedlak, L., T. Kodama, et al. (2009). "Chemical library screens targeting 
an HIV-1 accessory factor/host cell kinase complex identify novel 
antiretroviral compounds." ACS Chem Biol 4(11): 939-947. 
Eugenin, E. A., P. J. Gaskill, et al. (2009). "Tunneling nanotubes (TNT) are 
induced by HIV-infection of macrophages: a potential mechanism for 
intercellular HIV trafficking." Cell Immunol 254(2): 142-148. 
  142 
Fiala, M., T. Murphy, et al. (2004). "HAART drugs induce mitochondrial damage 
and intercellular gaps and gp120 causes apoptosis." Cardiovasc Toxicol 
4(4): 327-337. 
Fiala, M., W. Popik, et al. (2004). "HIV-1 induces cardiomyopathyby 
cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling." 
Cardiovasc Toxicol 4(2): 97-107. 
Fischer, M., H. F. Gunthard, et al. (2000). "Residual HIV-RNA levels persist for 
up to 2.5 years in peripheral blood mononuclear cells of patients on potent 
antiretroviral therapy." AIDS Res Hum Retroviruses 16(12): 1135-1140. 
Fischer, M., B. Joos, et al. (2004). "Cellular viral rebound after cessation of 
potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 
RNA encoding nef." J Infect Dis 190(11): 1979-1988. 
Fischer, M., B. Joos, et al. (2008). "Biphasic decay kinetics suggest progressive 
slowing in turnover of latently HIV-1 infected cells during antiretroviral 
therapy." Retrovirology 5: 107. 
Flammer, A. J., T. Anderson, et al. (2012). "The assessment of endothelial 
function: from research into clinical practice." Circulation 126(6): 753-767. 
Foster, J. L. and J. V. Garcia (2008). "HIV-1 Nef: at the crossroads." 
Retrovirology 5: 84. 
Foti, M., L. Cartier, et al. (1999). "The HIV Nef protein alters Ca(2+) signaling in 
myelomonocytic cells through SH3-mediated protein-protein interactions." 
J Biol Chem 274(49): 34765-34772. 
  143 
Foti, M., A. Mangasarian, et al. (1997). "Nef-mediated clathrin-coated pit 
formation." J Cell Biol 139(1): 37-47. 
Furtado, M. R., D. S. Callaway, et al. (1999). "Persistence of HIV-1 transcription 
in peripheral-blood mononuclear cells in patients receiving potent 
antiretroviral therapy." N Engl J Med 340(21): 1614-1622. 
Galvani, A. P. and M. Slatkin (2003). "Evaluating plague and smallpox as 
historical selective pressures for the CCR5-Delta 32 HIV-resistance 
allele." Proc Natl Acad Sci U S A 100(25): 15276-15279. 
Gerritsen, W. B., W. J. van Boven, et al. (2006). "Malondialdehyde in plasma, a 
biomarker of global oxidative stress during mini-CABG compared to on- 
and off-pump CABG surgery: a pilot study." Interact Cardiovasc Thorac 
Surg 5(1): 27-31. 
Gosling, J., S. Slaymaker, et al. (1999). "MCP-1 deficiency reduces susceptibility 
to atherosclerosis in mice that overexpress human apolipoprotein B." J 
Clin Invest 103(6): 773-778. 
Green, L. A., C. Kim, et al. (2012). "Pentoxifylline Reduces TNF-alpha and HIV-
induced Vascular Endothelial Activation." AIDS Res Hum Retroviruses. 
Green, L. A., D. Petrusca, et al. (2012). "Cigarette Smoke-Induced CXCR3 
Receptor Upregulation Mediates Endothelial Apoptosis." Am J Respir Cell 
Mol Biol 47(6): 807-814. 
Greenway, A., A. Azad, et al. (1995). "Human immunodeficiency virus type 1 Nef 
protein inhibits activation pathways in peripheral blood mononuclear cells 
and T-cell lines." J Virol 69(3): 1842-1850. 
  144 
Grunfeld, C., M. Pang, et al. (1992). "Lipids, lipoproteins, triglyceride clearance, 
and cytokines in human immunodeficiency virus infection and the acquired 
immunodeficiency syndrome." J Clin Endocrinol Metab 74(5): 1045-1052. 
Gunthard, H. F., D. V. Havlir, et al. (2001). "Residual human immunodeficiency 
virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital 
secretions and in cerebrospinal fluid after suppression of viremia for 2 
years." J Infect Dis 183(9): 1318-1327. 
Habibzadegah-Tari, P., K. G. Byer, et al. (2006). "Reactive oxygen species 
mediated calcium oxalate crystal-induced expression of MCP-1 in HK-2 
cells." Urol Res 34(1): 26-36. 
Haedicke, J., C. Brown, et al. (2009). "The brain-specific factor FEZ1 is a 
determinant of neuronal susceptibility to HIV-1 infection." Proc Natl Acad 
Sci U S A 106(33): 14040-14045. 
Hallenberger, S., V. Bosch, et al. (1992). "Inhibition of furin-mediated cleavage 
activation of HIV-1 glycoprotein gp160." Nature 360(6402): 358-361. 
Hanna, Z., E. Priceputu, et al. (2009). "Selective expression of human 
immunodeficiency virus Nef in specific immune cell populations of 
transgenic mice is associated with distinct AIDS-like phenotypes." J Virol 
83(19): 9743-9758. 
Hanna, Z., X. Weng, et al. (2001). "The pathogenicity of human 
immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is 
abolished by mutation of its SH3-binding domain, and disease 
development is delayed in the absence of Hck." J Virol 75(19): 9378-9392. 
  145 
Hansen, L., I. Parker, et al. (2013). "Endothelial dysfunction, arterial stiffening, 
and intima-media thickening in large arteries from HIV-1 transgenic mice." 
Ann Biomed Eng 41(4): 682-693. 
Heitzer, T., T. Schlinzig, et al. (2001). "Endothelial dysfunction, oxidative stress, 
and risk of cardiovascular events in patients with coronary artery disease." 
Circulation 104(22): 2673-2678. 
Heumuller, S., S. Wind, et al. (2008). "Apocynin is not an inhibitor of vascular 
NADPH oxidases but an antioxidant." Hypertension 51(2): 211-217. 
Hiipakka, M., P. Huotari, et al. (2001). "Inhibition of cellular functions of HIV-1 Nef 
by artificial SH3 domains." Virology 286(1): 152-159. 
Hill, M., G. Tachedjian, et al. (2005). "The packaging and maturation of the HIV-1 
Pol proteins." Curr HIV Res 3(1): 73-85. 
Hodis, H. N., W. J. Mack, et al. (2002). "Alpha-tocopherol supplementation in 
healthy individuals reduces low-density lipoprotein oxidation but not 
atherosclerosis: the Vitamin E Atherosclerosis Prevention Study 
(VEAPS)." Circulation 106(12): 1453-1459. 
Hofker, M. H., B. J. van Vlijmen, et al. (1998). "Transgenic mouse models to 
study the role of APOE in hyperlipidemia and atherosclerosis." 
Atherosclerosis 137(1): 1-11. 
Hofman, F. M., A. D. Wright, et al. (1993). "Exogenous tat protein activates 
human endothelial cells." Blood 82(9): 2774-2780. 
  146 
Hsue, P. Y., P. W. Hunt, et al. (2009). "Role of viral replication, antiretroviral 
therapy, and immunodeficiency in HIV-associated atherosclerosis." AIDS 
23(9): 1059-1067. 
Hunt, P. W. (2010). "Th17, gut, and HIV: therapeutic implications." Curr Opin HIV 
AIDS 5(2): 189-193. 
Hurlimann, D., R. Chenevard, et al. (2006). "Effects of statins on endothelial 
function and lipid profile in HIV infected persons receiving protease 
inhibitor-containing anti-retroviral combination therapy: a randomised 
double blind crossover trial." Heart 92(1): 110-112. 
Jawien, J., P. Nastalek, et al. (2004). "Mouse models of experimental 
atherosclerosis." J Physiol Pharmacol 55(3): 503-517. 
Jeremy, J. Y., D. P. Mikhailidis, et al. (1995). "Cigarette smoking and 
cardiovascular disease." J R Soc Health 115(5): 289-295. 
Jiang, J., W. Fu, et al. (2010). "HIV gp120 induces endothelial dysfunction in 
tumour necrosis factor-alpha-activated porcine and human endothelial 
cells." Cardiovasc Res 87(2): 366-374. 
Johnson, D. K., K. J. Schillinger, et al. (2002). "Inhibition of NADPH oxidase 
activation in endothelial cells by ortho-methoxy-substituted catechols." 
Endothelium 9(3): 191-203. 
Johnson, M. A., J. C. Gathe, Jr., et al. (2006). "A once-daily lopinavir/ritonavir-
based regimen provides noninferior antiviral activity compared with a 
twice-daily regimen." J Acquir Immune Defic Syndr 43(2): 153-160. 
  147 
Jolicoeur, P. (2011). "The CD4C/HIV(Nef)transgenic model of AIDS." Curr HIV 
Res 9(7): 524-530. 
Kanmogne, G. D., C. Primeaux, et al. (2005). "Induction of apoptosis and 
endothelin-1 secretion in primary human lung endothelial cells by HIV-1 
gp120 proteins." Biochem Biophys Res Commun 333(4): 1107-1115. 
Kay, D. G., P. Yue, et al. (2002). "Cardiac disease in transgenic mice expressing 
human immunodeficiency virus-1 nef in cells of the immune system." Am J 
Pathol 161(1): 321-335. 
Kinlay, S., D. Behrendt, et al. (2004). "Long-term effect of combined vitamins E 
and C on coronary and peripheral endothelial function." J Am Coll Cardiol 
43(4): 629-634. 
Kline, E. R., D. J. Kleinhenz, et al. (2008). "Vascular oxidative stress and nitric 
oxide depletion in HIV-1 transgenic rats are reversed by glutathione 
restoration." Am J Physiol Heart Circ Physiol 294(6): H2792-2804. 
Kline, E. R. and R. L. Sutliff (2008). "The roles of HIV-1 proteins and antiretroviral 
drug therapy in HIV-1-associated endothelial dysfunction." J Investig Med 
56(5): 752-769. 
Koga, M., H. Kai, et al. (2007). "Inhibition of progression and stabilization of 
plaques by postnatal interferon-gamma function blocking in ApoE-
knockout mice." Circ Res 101(4): 348-356. 
Kojda, G. and D. Harrison (1999). "Interactions between NO and reactive oxygen 
species: pathophysiological importance in atherosclerosis, hypertension, 
diabetes and heart failure." Cardiovasc Res 43(3): 562-571. 
  148 
Kuller, L. H., R. Tracy, et al. (2008). "Inflammatory and coagulation biomarkers 
and mortality in patients with HIV infection." PLoS Med 5(10): e203. 
Le Gall, S., L. Erdtmann, et al. (1998). "Nef interacts with the mu subunit of 
clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I 
molecules." Immunity 8(4): 483-495. 
Lenassi, M., G. Cagney, et al. (2010). "HIV Nef is secreted in exosomes and 
triggers apoptosis in bystander CD4+ T cells." Traffic 11(1): 110-122. 
Liu, X. L., P. F. Zhang, et al. (2012). "Local gene silencing of monocyte 
chemoattractant protein-1 prevents vulnerable plaque disruption in 
apolipoprotein E-knockout mice." PLoS One 7(3): e33497. 
Lo, I. C., J. M. Shih, et al. (2005). "Reactive oxygen species and ERK 1/2 
mediate monocyte chemotactic protein-1-stimulated smooth muscle cell 
migration." J Biomed Sci 12(2): 377-388. 
Lock, M., M. E. Greenberg, et al. (1999). "Two elements target SIV Nef to the 
AP-2 clathrin adaptor complex, but only one is required for the induction of 
CD4 endocytosis." EMBO J 18(10): 2722-2733. 
Lu, K., X. Heng, et al. (2011). "Structural determinants and mechanism of HIV-1 
genome packaging." J Mol Biol 410(4): 609-633. 
Luo, W. and B. M. Peterlin (1997). "Activation of the T-cell receptor signaling 
pathway by Nef from an aggressive strain of simian immunodeficiency 
virus." J Virol 71(12): 9531-9537. 
  149 
Mackay, C. R., W. L. Marston, et al. (1990). "Naive and memory T cells show 
distinct pathways of lymphocyte recirculation." J Exp Med 171(3): 801-
817. 
Magalhaes, M. G., B. Greenberg, et al. (2007). "Comorbidities in older patients 
with HIV: a retrospective study." J Am Dent Assoc 138(11): 1468-1475. 
Manninen, A., M. Hiipakka, et al. (1998). "SH3-Domain binding function of HIV-1 
Nef is required for association with a PAK-related kinase." Virology 250(2): 
273-282. 
Marecki, J. C., C. D. Cool, et al. (2006). "HIV-1 Nef is associated with complex 
pulmonary vascular lesions in SHIV-nef-infected macaques." Am J Respir 
Crit Care Med 174(4): 437-445. 
Mendall, M. A., P. Patel, et al. (1997). "Relation of serum cytokine concentrations 
to cardiovascular risk factors and coronary heart disease." Heart 78(3): 
273-277. 
Merchant, A. T., G. Msamanga, et al. (2005). "Multivitamin supplementation of 
HIV-positive women during pregnancy reduces hypertension." J Nutr 
135(7): 1776-1781. 
Miller, S. J., B. J. Coppinger, et al. (2010). "Antioxidants reverse age-related 
collateral growth impairment." J Vasc Res 47(2): 108-114. 
Mitola, S., R. Soldi, et al. (2000). "Identification of specific molecular structures of 
human immunodeficiency virus type 1 Tat relevant for its biological effects 
on vascular endothelial cells." J Virol 74(1): 344-353. 
  150 
Mugge, A. (1998). "The role of reactive oxygen species in atherosclerosis." Z 
Kardiol 87(11): 851-864. 
Mujawar, Z., H. Rose, et al. (2006). "Human immunodeficiency virus impairs 
reverse cholesterol transport from macrophages." PLoS Biol 4(11): e365. 
Mukai, Y., Y. Rikitake, et al. (2006). "Decreased vascular lesion formation in mice 
with inducible endothelial-specific expression of protein kinase Akt." J Clin 
Invest 116(2): 334-343. 
Muratori, C., L. E. Cavallin, et al. (2009). "Massive secretion by T cells is caused 
by HIV Nef in infected cells and by Nef transfer to bystander cells." Cell 
Host Microbe 6(3): 218-230. 
Napoli, C. and L. J. Ignarro (2001). "Nitric oxide and atherosclerosis." Nitric 
Oxide 5(2): 88-97. 
Nathan, D. M., J. Lachin, et al. (2003). "Intensive diabetes therapy and carotid 
intima-media thickness in type 1 diabetes mellitus." N Engl J Med 348(23): 
2294-2303. 
Nautiyal, M., A. C. Arnold, et al. (2013). "The brain Renin-Angiotensin system 
and mitochondrial function: influence on blood pressure and baroreflex in 
transgenic rat strains." Int J Hypertens 2013: 136028. 
Ohman, M. K., A. P. Wright, et al. (2010). "Monocyte chemoattractant protein-1 
deficiency protects against visceral fat-induced atherosclerosis." 
Arterioscler Thromb Vasc Biol 30(6): 1151-1158. 
  151 
Olivetta, E., D. Pietraforte, et al. (2005). "HIV-1 Nef regulates the release of 
superoxide anions from human macrophages." Biochem J 390(Pt 2): 591-
602. 
Oram, J. F. and R. M. Lawn (2001). "ABCA1. The gatekeeper for eliminating 
excess tissue cholesterol." J Lipid Res 42(8): 1173-1179. 
Pech-Amsellem, M. A., I. Myara, et al. (1996). "Enhanced modifications of low-
density lipoproteins (LDL) by endothelial cells from smokers: a possible 
mechanism of smoking-related atherosclerosis." Cardiovasc Res 31(6): 
975-983. 
Pollard, V. W. and M. H. Malim (1998). "The HIV-1 Rev protein." Annu Rev 
Microbiol 52: 491-532. 
Poon, D. T., J. Wu, et al. (1996). "Charged amino acid residues of human 
immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA 
packaging and infectivity." J Virol 70(10): 6607-6616. 
Pope, M. and A. T. Haase (2003). "Transmission, acute HIV-1 infection and the 
quest for strategies to prevent infection." Nat Med 9(7): 847-852. 
Priceputu, E., Z. Hanna, et al. (2007). "Primary human immunodeficiency virus 
type 1 nef alleles show major differences in pathogenicity in transgenic 
mice." J Virol 81(9): 4677-4693. 
Qiao, X., B. He, et al. (2006). "Human immunodeficiency virus 1 Nef suppresses 
CD40-dependent immunoglobulin class switching in bystander B cells." 
Nat Immunol 7(3): 302-310. 
  152 
Rajashekhar, G., D. O. Traktuev, et al. (2008). "IFATS collection: Adipose 
stromal cell differentiation is reduced by endothelial cell contact and 
paracrine communication: role of canonical Wnt signaling." Stem Cells 
26(10): 2674-2681. 
Rhew, D. C., M. Bernal, et al. (2003). "Association between protease inhibitor 
use and increased cardiovascular risk in patients infected with human 
immunodeficiency virus: a systematic review." Clin Infect Dis 37(7): 959-
972. 
Riccioni, G., A. Frigiola, et al. (2012). "Vitamin C and E consumption and 
coronary heart disease in men." Front Biosci (Elite Ed) 4: 373-380. 
Ross, R. (1999). "Atherosclerosis--an inflammatory disease." N Engl J Med 
340(2): 115-126. 
Rudel, T., F. T. Zenke, et al. (1998). "p21-activated kinase (PAK) is required for 
Fas-induced JNK activation in Jurkat cells." J Immunol 160(1): 7-11. 
Rudnicka, D., J. Feldmann, et al. (2009). "Simultaneous cell-to-cell transmission 
of human immunodeficiency virus to multiple targets through 
polysynapses." J Virol 83(12): 6234-6246. 
Rudnicka, D. and O. Schwartz (2009). "Intrusive HIV-1-infected cells." Nat 
Immunol 10(9): 933-934. 
Salmen, S., M. Colmenares, et al. (2010). "HIV-1 Nef associates with p22-phox, 
a component of the NADPH oxidase protein complex." Cell Immunol 
263(2): 166-171. 
  153 
Schluter, T., A. C. Steinbach, et al. (2008). "Apocynin-induced vasodilation 
involves Rho kinase inhibition but not NADPH oxidase inhibition." 
Cardiovasc Res 80(2): 271-279. 
Schrager, J. A. and J. W. Marsh (1999). "HIV-1 Nef increases T cell activation in 
a stimulus-dependent manner." Proc Natl Acad Sci U S A 96(14): 8167-
8172. 
Sehgal, P. B., S. Mukhopadhyay, et al. (2009). "Golgi dysfunction is a common 
feature in idiopathic human pulmonary hypertension and vascular lesions 
in SHIV-nef-infected macaques." Am J Physiol Lung Cell Mol Physiol 
297(4): L729-737. 
Sepkowitz, K. A. (2001). "AIDS--the first 20 years." N Engl J Med 344(23): 1764-
1772. 
Shafran, S. D., L. D. Mashinter, et al. (2005). "The effect of low-dose ritonavir 
monotherapy on fasting serum lipid concentrations." HIV Med 6(6): 421-
425. 
Sowinski, S., C. Jolly, et al. (2008). "Membrane nanotubes physically connect T 
cells over long distances presenting a novel route for HIV-1 transmission." 
Nat Cell Biol 10(2): 211-219. 
Stein, J. H., M. A. Merwood, et al. (2004). "Effects of pravastatin on lipoproteins 
and endothelial function in patients receiving human immunodeficiency 
virus protease inhibitors." Am Heart J 147(4): E18. 
  154 
Stolp, B., A. Imle, et al. (2012). "HIV-1 Nef interferes with T-lymphocyte 
circulation through confined environments in vivo." Proc Natl Acad Sci U S 
A 109(45): 18541-18546. 
Subramanian, S., A. Tawakol, et al. (2012). "Arterial inflammation in patients with 
HIV." JAMA 308(4): 379-386. 
Sundquist, W. I. and H. G. Krausslich (2012). "HIV-1 assembly, budding, and 
maturation." Cold Spring Harb Perspect Med 2(7): a006924. 
Swigut, T., N. Shohdy, et al. (2001). "Mechanism for down-regulation of CD28 by 
Nef." EMBO J 20(7): 1593-1604. 
Tracy, R. P., B. M. Psaty, et al. (1997). "Lifetime smoking exposure affects the 
association of C-reactive protein with cardiovascular disease risk factors 
and subclinical disease in healthy elderly subjects." Arterioscler Thromb 
Vasc Biol 17(10): 2167-2176. 
Triant, V. A., H. Lee, et al. (2007). "Increased acute myocardial infarction rates 
and cardiovascular risk factors among patients with human 
immunodeficiency virus disease." J Clin Endocrinol Metab 92(7): 2506-
2512. 
Ullrich, C. K., J. E. Groopman, et al. (2000). "HIV-1 gp120- and gp160-induced 
apoptosis in cultured endothelial cells is mediated by caspases." Blood 
96(4): 1438-1442. 
Viel, E. C., K. Benkirane, et al. (2008). "Xanthine oxidase and mitochondria 
contribute to vascular superoxide anion generation in DOCA-salt 
hypertensive rats." Am J Physiol Heart Circ Physiol 295(1): H281-288. 
  155 
Vilhardt, F., O. Plastre, et al. (2002). "The HIV-1 Nef protein and phagocyte 
NADPH oxidase activation." J Biol Chem 277(44): 42136-42143. 
Wang, S. W. and A. Aldovini (2002). "RNA incorporation is critical for retroviral 
particle integrity after cell membrane assembly of Gag complexes." J Virol 
76(23): 11853-11865. 
Wyatt, R. and J. Sodroski (1998). "The HIV-1 envelope glycoproteins: fusogens, 
antigens, and immunogens." Science 280(5371): 1884-1888. 
Xu, W., P. A. Santini, et al. (2009). "HIV-1 evades virus-specific IgG2 and IgA 
responses by targeting systemic and intestinal B cells via long-range 
intercellular conduits." Nat Immunol 10(9): 1008-1017. 
Yang, F., C. Q. Liu, et al. (2010). "[HIV-1 Nef regulates ICAM-1 expression on 
endothelial cells via Erk /Mapk signaling pathway]." Xi Bao Yu Fen Zi Mian 
Yi Xue Za Zhi 26(1): 44-46. 
Yokode, M., T. Kita, et al. (1988). "Cholesteryl ester accumulation in 
macrophages incubated with low density lipoprotein pretreated with 
cigarette smoke extract." Proc Natl Acad Sci U S A 85(7): 2344-2348. 
Zhang, H., R. J. Pomerantz, et al. (2000). "Human immunodeficiency virus type 1 
Vif protein is an integral component of an mRNP complex of viral RNA and 
could be involved in the viral RNA folding and packaging process." J Virol 
74(18): 8252-8261. 
Zhang, X., J. Yu, et al. (2012). "Slit2/Robo4 signaling modulates HIV-1 gp120-
induced lymphatic hyperpermeability." PLoS Pathog 8(1): e1002461. 
  156 
Zheng, Y. H., N. Lovsin, et al. (2005). "Newly identified host factors modulate HIV 
replication." Immunol Lett 97(2): 225-234. 
Zhou, Z., A. Pyriochou, et al. (2008). "Soluble guanylyl cyclase activation by 
HMR-1766 (ataciguat) in cells exposed to oxidative stress." Am J Physiol 
Heart Circ Physiol 295(4): H1763-1771. 
 
  
CURRICULUM VITAE 
Ting Wang 
Educational Background  
 
2010-2014 Indiana University, Indianapolis, IN  
Ph.D., Dept. of Microbiology and Immunology  
Advisor: Matthias Clauss, Ph.D.  
 
2008-2010 Indiana University, Indianapolis, IN  
Master of Science, Dept. of Microbiology and Immunology  
Advisor: Johnny He, Ph.D.  
 
2003-2006 The University of Sheffield, U.K. 
B.S., Dept of Biotechnology 
 
Research Experience  
 
2011-2013 VA Hospital, Indianapolis, IN 
Graduate research assistant under Matthias Clauss, Ph.D 
 
2007-2010 Indiana University School of Medicine, Indianapolis, IN 
Research Assistant under Johnny J. He, Ph.D.  
 
2006 The University of Sheffield, U.K 
Undergraduate research assistant under David Hornby, Ph.D 
 
Teaching Experience 
 
2010 Indiana University School of Nursing, Indianapolis, IN  
Teaching Assistant in Microbiology J210, “Nursing Microbiology”  
 
Grants and Fellowships  
 
2013-2014 Two year pre-doc fellowship from American Heart Association 
2012 Education Enhancement travel grant 
 
Publications 
 
Wang, Ting, Green, Linden, Gupta, Samir, Jolicoeur, John, Clauss, Matthias. 
Transfer of Intracellular HIV-1 Nef to endothelium causes MCP-1 release and 
induction of apoptosis. Plos One, 2014 
 
 
  
Wang, Ting, Green, Linden, Gupta, Yu,Qigui, Clauss, Matthias. Intracellular Nef 
detected in CD4+ and CD4- PBMCs from HIV patients. In revision 
 
Green, Linden, Yi, Ru, Petrusca, Daniela, Wang, Ting, Elghouche, Alhasan, 
Gupta, Samir Petrache, Irina, Clauss, Matthias. Autocrine mechanism of HIV 
envelope protein gp120-induced apoptosis in lung microvascular endothelial 
cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 
2013 
 
Wang, Ting, Green, Linden, He, Johnny J. The effects of herbal extracts on HIV-
1 replication. (To be submitted) 
 
Park, In-Woo, Han, Changri, Green, Linden A, Wang, Ting, Liu, Ying, Cen, 
Changchun, Song, Xinming, Yang, Biao, Chen, Guangying, He, Johnny J. 
Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal 
herbal plants. BMC Complementary & Alternative Medicine 2009 
 
 
Abstracts: 
 
“Dissemination of HIV-Nef in HIV-infected population: protein transfer and 
apoptosis induction in lymphatic endothelium”. North American Vascular Biology 
Organization, New Haven, Connecticut, May 2013. 
 
“Transfer of Intracellular HIV-Nef to Endothelium Causes MCP-1 Release and 
Induction of Apoptosis”. Arteriosclerosis, Thrombosis, and Vascular Biology, 
Lake Buena Vista, Florida, May 2013 
 
“A novel role of HIV-1 Nef in Endothelial dysfunction”. Basic Cardiovascular 
Scientific Section, New Orleans, Louisiana, July 2012 
 
 
